prednisone and Local Neoplasm Recurrence studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

Excerpt	Relevance	Reference
" After discontinuation of lenalidomide, he had no arthritis relapse; it was then concluded that the patient had a lenalidomide-induced arthritis."	9.22	Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases. ( Despas, F; Gauthier, M; Icard, C; Mocquot, P; Nogaro, JC, 2022)
"During the Rituximab era, high dose intravenous methotrexate (HD) and intrathecal methotrexate (IT) are recommended prophylaxis in preventing central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) patients."	9.22	Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. ( Liu, B; Shi, X; Wang, Z; Xie, X; Xu, D; Zhang, N, 2022)
"This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma."	9.20	Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. ( Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S, 2015)
"This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)."	9.14	Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010)
"Eighty-two adult patients with advanced B-lymphoma, treated between 1981 and 1983 with VEPA (vincristine, cyclophosphamide, prednisolone and doxorubicin) or VEPA-M (VEPA plus methotrexate) in a prospective randomized fashion, were evaluated for pretreatment characteristics."	9.06	Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M). ( Kikuchi, M; Konda, S; Minato, K; Ogawa, M; Ota, K; Shimoyama, M; Takatsuki, K; Tominaga, S; Tsugane, S; Yunoki, K, 1988)
"After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone."	9.05	Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985)
"Approximately 40% patients of diffuse large B-cell lymphoma (DLBCL) would develop disease recurrence/progression after first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis."	8.31	Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma. ( Ding, K; Jiang, X; Wang, X; Yu, L, 2023)
" Over the past 10 years, the association between clozapine, which is the criterion standard treatment for refractory schizophrenia, and hematological malignancies has been described."	8.31	Diffuse Large B-Cell Lymphoma with Cutaneous Manifestations in a Young Patient Using Clozapine for Schizophrenia: A Case Report. ( Alves Junior, MP; Gouveia, PADC; Guedes, MMV; Lira, AC; Moraes de Brito, MC; Nascimento, JDS; Pimentel Jatobá, V, 2023)
"This study evaluated the efficacy of central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX) in patients with diffuse large B-cell lymphoma (DLBCL)."	7.81	Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. ( Fujimaki, K; Hagihara, M; Hashimoto, C; Ishibashi, D; Ishigatsubo, Y; Ishii, Y; Ishiyama, Y; Kishimoto, K; Koyama, S; Motomura, S; Numata, A; Ohshima, R; Sakai, R; Tachibana, T; Taguchi, J; Takahashi, H; Takasaki, H; Takemura, S; Tomita, N; Watanabe, R, 2015)
"We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions."	7.81	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lympho ( Ahn, JS; Bae, SH; Do, YR; Go, SI; Hong, J; Kang, HJ; Kim, HJ; Kim, JS; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, WS; Kim, YR; Lee, B; Lee, GW; Lee, H; Lee, SI; Lee, WS; Oh, S; Oh, SY; Song, MK; Suh, C; Yhim, HY, 2015)
"To assess the efficacy and tolerability of weekly oral cyclophosphamide in combination with alternate-day prednisone (CP) as salvage therapy for patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (ASCT)."	7.73	Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. ( Chen, CI; Jaksic, W; Mikhael, J; Pond, GR; Reece, DE; Stewart, AK; Trieu, Y; Trudel, S, 2005)
"Remarkable results of the treatment of refractory multiple myeloma with thalidomide have been reported."	7.72	Low dose thalidomide in patients with relapsed or refractory multiple myeloma. ( Ackermann, J; Dimou, G; Drach, J; Gisslinger, H; Kees, M; Lechner, K; Sillaber, C, 2003)
"The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients."	7.69	Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. ( Boyko, OB; Brizel, DM; Brown, MT; Burger, PC; Gockerman, JP; Halperin, EC; Lachance, DH; Schold, SC, 1994)
"Over a 24-year period, 62 infants (47 girls) with hemangiomas were treated with an initial dose of either 3 or 5 mg/kg/day of oral prednisone for 2 weeks, after which the dose was gradually tapered off during 6-8 weeks."	7.69	[High dose oral prednisone for hemangiomas in infants]. ( Sadan, N; Wolach, B, 1997)
"33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)."	7.67	M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988)
"Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine."	7.66	Clinical trial of nafoxidine in advanced breast cancer. ( De Jager, RL; Krakoff, IH; Steinbaum, FL, 1978)
" We conducted a phase II study to investigate the efficacy and safety of dose-adjusted (DA)- EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) combined with high-dose methotrexate (HD-MTX) in newly diagnosed patients with CD5+ DLBCL."	6.94	DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. ( Asano, N; Igarashi, T; Izutsu, K; Katayama, N; Kato, K; Kinoshita, T; Miyawaki, K; Miyazaki, K; Nishikawa, M; Nishikori, M; Nishimura, Y; Ohata, K; Ohshima, K; Okamoto, M; Sakai, R; Sunami, K; Suzumiya, J; Takahashi, N; Tamaru, S; Yamada, T; Yamaguchi, M; Yamamoto, G; Yano, H; Yoshida, I, 2020)
"Everolimus has single-agent activity in lymphoma."	6.87	Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. ( Belada, D; Bermudez Silva, CD; Bouabdallah, K; Cavalli, F; Costa, LJ; Fan, J; Fayad, L; Hino, M; Ikeda, T; Kattan, JG; Kim, WS; Kuruvilla, J; Larouche, JF; Louveau, AL; Mayer, J; Ogura, M; Ozcan, M; Rigacci, L; Shi, Y; Tobinai, K; Vanazzi, A; Voi, M; Witzig, TE; Wu, C; Zhu, J, 2018)
"Lenalidomide 10 mg/d was identified as the MTD because, in the 15 mg cohort, one patient experienced dose-limiting toxicity (grade 3 angioedema) and two patients had mobilization failure."	6.82	Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. ( Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A, 2016)
" They were then assigned at random to receive no further therapy (NT), ovarian irradiation (R) 2000 rads in 5 days, or ovarian irradiation in the same dosage plus prednisone (R + P) 7."	6.68	Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. ( Allt, WE; Beale, FA; Bulbrook, RD; Bush, RS; Clark, RM; Fitzpatrick, PJ; Hawkins, NV; Hayward, JL; Jenkin, RD; Meakin, JW; Panzarella, T; Pringle, JF; Rider, WD, 1996)
"172 patients who had had mastectomy for breast cancer were treated by repeated adjuvant chemotherapy, either with phenylalanine mustard (P."	6.64	Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Hahn, RG; Ingle, JN; O'Connell, MJ; O'Fallon, JR; Payne, WS; Rubin, J; Scanlon, PW, 1978)
"Most patients with diffuse large B-cell lymphoma (DLBCL) can be cured with immunochemotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)."	5.69	Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis. ( Altmann, B; Casasnovas, O; Chartier, L; Fitoussi, O; Frontzek, F; Glass, B; Haioun, C; Held, G; Ketterer, N; Lenz, G; Molina, T; Morschhauser, F; Mounier, N; Ott, G; Poeschel, V; Récher, C; Renaud, L; Rosenwald, A; Schmitz, N; Thieblemont, C; Tilly, H; Ziepert, M, 2023)
"Thalidomide is a medication with strong anti-inflammatory, immunomodulatory, antiangiogenic, and sedative properties."	5.56	Thalidomide as a potential adjuvant treatment for paraneoplastic pemphigus: A single-center experience. ( Pan, M; Wang, J; Zhang, Y, 2020)
"In the group of high-grade malignant lymphomas there were 39% complete remission, 37% partial remission, and 24% without response."	5.26	[Results of chemotherapy with cyclophosphamide, vincristine, methotrexate and prednisone in recurring or disseminated non-Hodgkin lymphomas in the University of Kiel Radiology Clinic]. ( Liffers, R, 1981)
"This study aimed to evaluate the efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treating patients with diffuse large B-cell lymphoma (DLBCL)."	5.24	Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma. ( Ding, SS; Guo, L; Hu, X; Li, S; Liang, X; Wen, SJ; Yang, SE; Zeng, M, 2017)
" After discontinuation of lenalidomide, he had no arthritis relapse; it was then concluded that the patient had a lenalidomide-induced arthritis."	5.22	Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases. ( Despas, F; Gauthier, M; Icard, C; Mocquot, P; Nogaro, JC, 2022)
"During the Rituximab era, high dose intravenous methotrexate (HD) and intrathecal methotrexate (IT) are recommended prophylaxis in preventing central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) patients."	5.22	Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. ( Liu, B; Shi, X; Wang, Z; Xie, X; Xu, D; Zhang, N, 2022)
"This single institution, open label Phase I-II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma."	5.20	Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. ( Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S, 2015)
"This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)."	5.14	Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010)
"One hundred ninety-five women (141 eligible) whose disease was in CR or in CR except for bone metastases following six cycles (6 months) of doxorubicin-containing induction treatment were randomized to receive cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, and halotestin [CMF(P)TH] or observation."	5.08	Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. ( Abeloff, MD; Cummings, FJ; Falkson, G; Gelman, RS; Osborne, CK; Pandya, KJ; Sledge, GW; Tormey, D, 1998)
"A randomised trial has previously been repeated in which 437 women with node positive breast cancer received either a 12-week chemohormonal regimen consisting of cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, adriamycin and tamoxifen or 36 weeks of CMFVP."	5.07	The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. ( Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Gent, M; Goodyear, MD; Levine, MN; Skillings, J, 1992)
"A randomized trial has been performed in which women with axillary node-positive breast cancer were allocated to either a short intensive 12-week chemohormonal treatment consisting of cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and tamoxifen (CMFVP plus AT) or 36 weeks of CMFVP."	5.06	A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. ( Abu-Zahra, H; Arnold, A; Bramwell, V; DePauw, S; Findlay, B; Gent, M; Hryniuk, WM; Levin, L; Levine, MN; Skillings, J, 1990)
"We have evaluated the results of salvage systemic therapy in 257 patients with breast cancer recurrent after surgical adjuvant treatment with cyclophosphamide, fluorouracil, and prednisone (CFP) with or without tamoxifen."	5.06	Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. ( Ahmann, DL; Buckner, JC; Cullinan, SA; Everson, LK; Ingle, JN; Krook, JE; O'Fallon, JR; Pfeifle, DM, 1989)
"Postmenopausal women who underwent modified radical mastectomy for Stage II, estrogen receptor (ER)-positive breast cancer were randomized to receive endocrine treatment (tamoxifen [T], 40 mg daily for 3 years) alone versus endocrine treatment plus five-drug chemotherapy (Cytoxan [cyclophosphamide, C], methotrexate [M], 5-fluorouracil [F], vincristine [V], and prednisone [P], CMFVP, for 1 year)."	5.06	Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. ( Arafah, BM; Crowe, JP; Gordon, NH; Hubay, CA; Marshall, JS; McGuire, W; Pearson, OH, 1989)
"Eight hundred eighteen premenopausal or perimenopausal breast cancer patients with axillary node metastases were treated with adjuvant chemotherapy (CMF) with or without endocrine treatment (prednisone, oophorectomy) in two concurrent prospective trials."	5.06	Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. ( Castiglione, M; Gelber, RD; Goldhirsch, A, 1988)
"Eighty-two adult patients with advanced B-lymphoma, treated between 1981 and 1983 with VEPA (vincristine, cyclophosphamide, prednisolone and doxorubicin) or VEPA-M (VEPA plus methotrexate) in a prospective randomized fashion, were evaluated for pretreatment characteristics."	5.06	Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M). ( Kikuchi, M; Konda, S; Minato, K; Ogawa, M; Ota, K; Shimoyama, M; Takatsuki, K; Tominaga, S; Tsugane, S; Yunoki, K, 1988)
"In 1977 we reported our results of an ongoing randomized clinical trial evaluating early or delayed adjuvant chemotherapy utilizing 5-flourouracil, cytoxan and prednisone in premenopausal patients with recurrent or advanced breast cancer."	5.05	An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Green, SJ; Hahn, RG; Ingle, JN; Lee, RA, 1982)
"After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone."	5.05	Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985)
"A number of cooperative-group and single-institution studies have shown that BCNU used in combination with prednisone alone or with melphalan,cyclophosphamide, and prednisone is useful for remission induction in patients with previously untreated multiple myeloma."	5.04	Nitrosoureas in multiple myeloma. ( Salmon, SE, 1976)
"Standard chemotherapy with melphalan-prednisone or a combination of alkylating agents has not extended the overall survival of patients with multiple myeloma during the last 30 years and strictly defined complete remissions (CR) are exceedingly rare."	4.79	Hematopoietic stem cell transplants for multiple myeloma. ( Barlogie, B; Bracy, D; Desikan, KR; Jagannath, S; Siegel, D; Tricot, G; Vesole, DH, 1996)
"Approximately 40% patients of diffuse large B-cell lymphoma (DLBCL) would develop disease recurrence/progression after first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) induction therapy, with highly poor prognosis."	4.31	Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma. ( Ding, K; Jiang, X; Wang, X; Yu, L, 2023)
" Over the past 10 years, the association between clozapine, which is the criterion standard treatment for refractory schizophrenia, and hematological malignancies has been described."	4.31	Diffuse Large B-Cell Lymphoma with Cutaneous Manifestations in a Young Patient Using Clozapine for Schizophrenia: A Case Report. ( Alves Junior, MP; Gouveia, PADC; Guedes, MMV; Lira, AC; Moraes de Brito, MC; Nascimento, JDS; Pimentel Jatobá, V, 2023)
"Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method."	4.12	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. ( Agbetiafa, K; Ahearne, M; Barlow, BR; Calimeri, T; Cheah, CY; Choquet, S; Clavert, A; Cwynarski, K; Durot, E; Ebsworth, TJ; El Galaly, TC; Elliot, J; Eyre, TA; Fernandez, R; Ferreri, AJM; Forgeard, N; Fox, CP; Gounder, P; Guidetti, A; Hamad, N; Htut, TW; Khwaja, J; Kirkwood, AA; Ku, M; Lebras, L; Lees, C; Lewis, KL; Liu, Q; Lombion, N; Lopez-Garcia, A; Manos, K; Martinez-Calle, N; McIlroy, G; McKay, P; Miall, F; Moles-Moreau, MP; Narkhede, M; O'Mahony, D; Preston, G; Renaud, L; Ricard, L; Roulin, L; Rusconi, C; Santarsieri, A; Schorb, E; Scott, H; Shah, N; Smith, J; Soussain, C; Strüßmann, T; Tchernonog, E; Vassallo, F; Wilson, MR; Wong Doo, N; Zayac, AS; Øvlisen, AK, 2022)
"The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-line rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone (R-CHOP) delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years with an aaIPI (age-adjusted International Prognostic Index) score ≥1 (registered as NCT00144755)."	4.12	Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. ( Belot, A; Bosly, A; Camus, V; Casasnovas, O; Delarue, R; Feugier, P; Fitoussi, O; Fruchart, C; Ghesquières, H; Haioun, C; Joubert, C; Michot, JM; Molina, TJ; Nicolas-Virelizier, E; Oberic, L; Sibon, D; Thieblemont, C; Tilly, H, 2022)
"Patients with angioimmunoblastic T-cell lymphoma (AITL) are treated with cyclophosphamide, doxorubicin, vincristine and prednisone with or without etoposide (CHO(E)P)."	4.12	Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. ( Böhmer, L; Brink, M; Diepstra, A; Huls, GA; Jansen, PM; Kersten, MJ; Meeuwes, FO; Mutsaers, PGNJ; Nijland, M; Oostvogels, R; Plattel, WJ; Snijders, TJF; van der Poel, MWM; Vermaat, JSP; Visser, O; Woei-A-Jin, S; Wondergem, M, 2022)
"One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy."	3.96	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. ( Arroyo-Solera, I; Casanova, I; Céspedes, MV; Falgàs, A; Gallardo, A; Mangues, MA; Mangues, R; Moreno, MJ; Pallarès, V; Sierra, J; Unzueta, U; Vázquez, E; Villaverde, A, 2020)
"About one third of patients with diffuse large B-cell lymphoma (DLBCL) relapse after receiving first-line (1L) treatment of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)."	3.91	Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. ( Broder, MS; Purdum, A; Reddy, SR; Tieu, R, 2019)
"Prognostic models for primary diffuse large B-cell lymphoma (DLBCL) resistant to or relapsing after initial therapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) have not been well-established."	3.85	Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study. ( Fukuda, T; Miura, O; Watanabe, K; Yamamoto, M, 2017)
"This study evaluated the efficacy of central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX) in patients with diffuse large B-cell lymphoma (DLBCL)."	3.81	Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone. ( Fujimaki, K; Hagihara, M; Hashimoto, C; Ishibashi, D; Ishigatsubo, Y; Ishii, Y; Ishiyama, Y; Kishimoto, K; Koyama, S; Motomura, S; Numata, A; Ohshima, R; Sakai, R; Tachibana, T; Taguchi, J; Takahashi, H; Takasaki, H; Takemura, S; Tomita, N; Watanabe, R, 2015)
"We evaluated the clinical outcomes and relapse patterns of 80 patients with primary sinonasal tract diffuse large B-cell lymphoma (SN-DLBCL) treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy at 22 institutions."	3.81	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lympho ( Ahn, JS; Bae, SH; Do, YR; Go, SI; Hong, J; Kang, HJ; Kim, HJ; Kim, JS; Kim, MK; Kim, SH; Kim, SJ; Kim, SY; Kim, WS; Kim, YR; Lee, B; Lee, GW; Lee, H; Lee, SI; Lee, WS; Oh, S; Oh, SY; Song, MK; Suh, C; Yhim, HY, 2015)
"The addition of rituximab to CHOP (R-CHOP; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improves outcome in patients with diffuse large B-cell lymphoma (DLBCL)."	3.76	Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. ( Connors, JM; Gascoyne, RD; Savage, KJ; Sehn, LH; Shenkier, TN; Villa, D, 2010)
"The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improved the outcome of patients with diffuse large B-cell lymphoma (DLBCL)."	3.76	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. ( Ahn, HK; Kim, JH; Kim, K; Kim, SJ; Kim, WS; Ko, YH; Won, YW; Yi, JH; Yun, J, 2010)
" Thus, we studied absolute lymphocyte count (ALC) as a marker of poststandard chemotherapy (rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP)) NHL relapse in patients with diffuse large B-cell lymphoma (DLBCL)."	3.76	Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. ( Ansell, SM; Colgan, JP; Habermann, TM; Inwards, DJ; Johnston, PB; Markovic, SN; Micallef, IN; Nowakowski, GS; Porrata, LF; Rsitow, K; Thompson, CA; Witzig, TE, 2010)
"To assess the efficacy and tolerability of weekly oral cyclophosphamide in combination with alternate-day prednisone (CP) as salvage therapy for patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (ASCT)."	3.73	Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. ( Chen, CI; Jaksic, W; Mikhael, J; Pond, GR; Reece, DE; Stewart, AK; Trieu, Y; Trudel, S, 2005)
"Remarkable results of the treatment of refractory multiple myeloma with thalidomide have been reported."	3.72	Low dose thalidomide in patients with relapsed or refractory multiple myeloma. ( Ackermann, J; Dimou, G; Drach, J; Gisslinger, H; Kees, M; Lechner, K; Sillaber, C, 2003)
"The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients."	3.69	Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. ( Boyko, OB; Brizel, DM; Brown, MT; Burger, PC; Gockerman, JP; Halperin, EC; Lachance, DH; Schold, SC, 1994)
"Over a 24-year period, 62 infants (47 girls) with hemangiomas were treated with an initial dose of either 3 or 5 mg/kg/day of oral prednisone for 2 weeks, after which the dose was gradually tapered off during 6-8 weeks."	3.69	[High dose oral prednisone for hemangiomas in infants]. ( Sadan, N; Wolach, B, 1997)
"33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)."	3.67	M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988)
"62 patients with multiple myeloma were primarily treated with the combination vincristin + melphalan + cyclophosphamide + prednisolone (VMCP)."	3.66	[Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma]. ( Anger, G; Wutke, K, 1983)
"Combination chemotherapy consisting of cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) was administered to 5 patients with invasive lymphoepithelial thymoma."	3.66	Combination chemotherapy in invasive thymoma role of COPP. ( Evans, WK; Feld, R; Phillips, MJ; Simpson, WJ; Thompson, DM, 1980)
"Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine."	3.66	Clinical trial of nafoxidine in advanced breast cancer. ( De Jager, RL; Krakoff, IH; Steinbaum, FL, 1978)
"In adults with advanced-stage Hodgkin's lymphoma, the CD30-directed antibody-drug conjugate brentuximab vedotin combined with multiagent chemotherapy has been shown to have greater efficacy, but also more toxic effects, than chemotherapy alone."	3.11	Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. ( Castellino, SM; Charpentier, AM; Cho, S; Dave, H; Henderson, TO; Hodgson, D; Hoppe, BS; Horton, T; Keller, FG; Kelly, KM; McCarten, K; Parsons, SK; Pei, Q; Punnett, A; Wu, Y, 2022)
"In men with biochemically recurrent prostate cancer following definitive treatment of the primary, finite duration treatment with ADT and Abi +P results in a significantly longer PSA relapse-free interval than treatment with ADT alone."	3.01	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. ( Alafis, I; Aparicio, A; Araujo, J; Boukovala, M; Chapin, BF; Corn, P; Davis, J; Efstathiou, E; Logothetis, CJ; Papadopoulos, J; Pruitt, L; Spetsieris, N; Subudhi, SK; Tu, SM; Wang, J; Wang, X; Weldon, JA; Zurita, A, 2021)
"The shocking fact was that re-biopsy of lymphadenopathy revealed peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL)."	3.01	Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review. ( Chen, B; Chen, P; Huang, F; Jin, X; Li, J; Liang, Y; Liu, H; Xiao, X; Yuan, X, 2023)
" Primary DLBCL of the central nervous system (CNS) (primary central nervous system lymphoma [PCNSL]) is an exception because of the low CNS bioavailability of related drugs."	2.94	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. ( Angelillo, P; Anzalone, N; Bordignon, C; Calimeri, T; Cattaneo, D; Ciceri, F; Citterio, G; Conte, GM; Corti, A; Curnis, F; De Lorenzo, D; Fallanca, F; Ferreri, AJM; Foppoli, M; Guggiari, E; Lopedote, P; Nonis, A; Politi, LS; Ponzoni, M; Rrapaj, E; Sassone, M; Scarano, E; Steffanoni, S; Tarantino, V, 2020)
" We conducted a phase II study to investigate the efficacy and safety of dose-adjusted (DA)- EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) combined with high-dose methotrexate (HD-MTX) in newly diagnosed patients with CD5+ DLBCL."	2.94	DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. ( Asano, N; Igarashi, T; Izutsu, K; Katayama, N; Kato, K; Kinoshita, T; Miyawaki, K; Miyazaki, K; Nishikawa, M; Nishikori, M; Nishimura, Y; Ohata, K; Ohshima, K; Okamoto, M; Sakai, R; Sunami, K; Suzumiya, J; Takahashi, N; Tamaru, S; Yamada, T; Yamaguchi, M; Yamamoto, G; Yano, H; Yoshida, I, 2020)
"Everolimus has single-agent activity in lymphoma."	2.87	Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. ( Belada, D; Bermudez Silva, CD; Bouabdallah, K; Cavalli, F; Costa, LJ; Fan, J; Fayad, L; Hino, M; Ikeda, T; Kattan, JG; Kim, WS; Kuruvilla, J; Larouche, JF; Louveau, AL; Mayer, J; Ogura, M; Ozcan, M; Rigacci, L; Shi, Y; Tobinai, K; Vanazzi, A; Voi, M; Witzig, TE; Wu, C; Zhu, J, 2018)
"Follicular lymphoma is an indolent lymphoma that remains incurable with standard approaches."	2.82	Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose? ( Ngu, H; Okosun, J; Phillips, T; Sehn, LH; Takiar, R, 2022)
"Lenalidomide 10 mg/d was identified as the MTD because, in the 15 mg cohort, one patient experienced dose-limiting toxicity (grade 3 angioedema) and two patients had mobilization failure."	2.82	Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. ( Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A, 2016)
"To investigate the clinical efficacy and safety between CHOPE regimen alone and it combined with thalidomide for relapsed and refractory non-Hodgkin's lymphoma."	2.82	[Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma]. ( Yang, YZ, 2016)
"To evaluate the safety, preliminary efficacy, and pharmacokinetics of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, in combination with the immunochemotherapeutic regimen, rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP), in patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma (NHL)."	2.82	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ( Ananthakrishnan, R; Boni, J; Crump, M; Davies, A; Hatake, K; Ishibashi, T; MacDonald, D; Ogura, M; Paccagnella, ML; Tobinai, K; Vandendries, E, 2016)
"The level of minimal residual disease during remission induction is the most important prognostic indicator in patients with acute lymphoblastic leukaemia (ALL)."	2.80	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. ( Bhojwani, D; Bowman, WP; Campana, D; Cheng, C; Coustan-Smith, E; Downing, JR; Evans, WE; Gruber, TA; Inaba, H; Jeha, S; Leung, WH; Pei, D; Pui, CH; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT, 2015)
"This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients."	2.77	Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. ( Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ, 2012)
"Disability after treatment due to pathological fracture was not seen."	2.76	Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. ( Barton, M; Christie, D; Dear, K; Le, T; Porter, D; Pratt, G; Roos, D; Wirth, A, 2011)
"Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL)."	2.76	Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. ( Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE, 2011)
"Late-onset ones were cataract and dry eye (5) (13."	2.74	[Role of modified radiotherapy in the combined treatment of orbital non-Hodgkin lymphoma]. ( Bochkareva, TN; Cherviakov, AM; Il'in, NV; Leenman, EE; Vinogradova, IuN, 2009)
"Treatment with etoposide also evolved as a prognostic factor because the risk of CNS failure was significantly reduced after CHOEP (P=0."	2.73	Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). ( Boehme, V; Kaiser, U; Kloess, M; Loeffler, M; Pfreundschuh, M; Schmitz, N; Zeynalova, S, 2007)
"Thirty-six untreated lymphoblastic lymphoma patients aged from 3 to 18 years were included, with 1 patient in stage II , 9 in stage III and 26 in stage IV."	2.73	[Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma]. ( Guan, ZZ; Huang, HQ; Li, YH; Ling, JY; Liu, DG; Sun, XF; Xia, Y; Xia, ZJ; Zhang, L; Zhen, ZJ; Zhou, ZM, 2007)
"A 31-year-old man with Crohn's disease in remission after 6-year treatment with infliximab developed nasopharyngeal diffuse large B cell lymphoma."	2.72	Long-term endoscopic remission in Crohn's disease after allogeneic hematopoietic stem cell transplantation for diffuse large B cell lymphoma: case report and literature review. ( Fukuhara, N; Handa, T; Ichikawa, S; Inomata, Y; Kakuta, Y; Kuroha, M; Masamune, A; Moroi, R; Sato, Y; Shiga, H; Shimoyama, Y; Takahashi, T, 2021)
" The dosage or drugs chosen for salvage therapy are limited by doxorubicin-induced cardiomyopathy."	2.71	Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin ( Hayama, M; Higashihara, M; Kajiwara, K; Khori, M; Niitsu, N; Tamaru, J, 2005)
" There was a highly significant difference in CR rates between weekly (69 of 71; 97%) and biweekly (60 of 73; 82%) PEG-Asp dosing (P =."	2.69	Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. ( Abshire, TC; Billett, AL; Bradley, P; Buchanan, GR; Pollock, BH, 2000)
"Women with metastatic breast cancer who had measurable disease, required laboratory tests, had received no prior chemotherapy for metastases, had a Cancer and Leukemia Group B (CALGB) performance status < or = 2, and provided informed consent were eligible."	2.68	Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. ( Abrams, J; Aisner, J; Budman, D; Cirrincione, C; Citron, M; Holland, J; Muss, H; Panasci, L; Perloff, M; Perry, M, 1995)
"Treatment of both Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG-NHL) with bulky presentation at diagnosis frequently results in residual masses detected radiologically."	2.68	Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. ( Babini, L; Barbieri, E; Battista, G; Bendandi, M; Canini, R; Fanti, S; Frezza, G; Gherlinzoni, F; Gozzetti, A; Merla, E; Monetti, N; Pisi, P; Rimondi, MR; Tura, S; Zinzani, PL; Zompatori, M, 1996)
" They were then assigned at random to receive no further therapy (NT), ovarian irradiation (R) 2000 rads in 5 days, or ovarian irradiation in the same dosage plus prednisone (R + P) 7."	2.68	Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. ( Allt, WE; Beale, FA; Bulbrook, RD; Bush, RS; Clark, RM; Fitzpatrick, PJ; Hawkins, NV; Hayward, JL; Jenkin, RD; Meakin, JW; Panzarella, T; Pringle, JF; Rider, WD, 1996)
"A retrospective review of patients with Hodgkin's disease treated at Stanford University Medical Center was undertaken to determine if, within the pediatric population, children < or = 10 years of age have a unique prognosis and response to treatment."	2.67	Hodgkin's disease in the very young. ( Cleary, SF; Donaldson, SS; Link, MP, 1994)
"Postoperative women with breast cancer but without histopathological evidence of metastases to the axillary lymph nodes or clinical evidence of metastases were studied."	2.67	Chemotherapy versus observation in high-risk node-negative breast cancer patients. ( Cooper, MR; Eudey, L; Falkson, G; Gilchrist, KW; Mansour, EG; Osborne, CK; Shatila, AH; Tormey, DC, 1992)
"Thirty seven Hodgkin's lymphoma patients with recurrence after first remission induced by radiation therapy and/or chemotherapy with mustine, oncovin, procarbazine and prednisolone (MOPP) were randomised to treat with a new combination chemotherapy comprising of doxorubicin, oncovin, procarbazine and prednisolone (DOPP)."	2.65	A new combination chemotherapy for recurrent Hodgkin's lymphoma. ( Ahmed, Q; Rahim, MA; Sarma, SK, 1982)
" They were then assigned at random to receive no further therapy, ovarian irradiation (2000 rads in 5 days) or ovarian irradiation in the same dosage plus prednisone, 7."	2.65	Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. ( Allt, WE; Beale, FA; Brown, TC; Bulbrook, RD; Bush, RS; Clark, RM; Fitzpatrick, PJ; Hawkins, NV; Hayward, JL; Jenkin, RD; Meakin, JW; Pringle, JF; Reid, JG; Rider, WD, 1979)
"172 patients who had had mastectomy for breast cancer were treated by repeated adjuvant chemotherapy, either with phenylalanine mustard (P."	2.64	Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Frytak, S; Hahn, RG; Ingle, JN; O'Connell, MJ; O'Fallon, JR; Payne, WS; Rubin, J; Scanlon, PW, 1978)
"Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration."	2.53	[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016)
"Despite many recent advances in the treatment of multiple myeloma, the course of the disease is characterized by a repeating pattern of periods of remission and relapse as patients cycle through the available treatment options."	2.52	Maintenance therapy for multiple myeloma in the era of novel agents. ( Facon, T, 2015)
"As with other indolent lymphomas, follicular lymphoma is felt to be highly treatable, but ultimately incurable."	2.49	The optimal management of follicular lymphoma: an evolving field. ( Cheson, BD; Ujjani, C, 2013)
"A 47 year old woman with a MALT lymphoma affecting the breast exclusively is reported."	2.40	[Primary MALT-type lymphoma of the breast]. ( Campo, E; Cervantes, F; Esteve, J; Montserrat, E; Rafel, M; Serra, A; Velasco, M, 1998)
"The term "hormone-refractory" prostate cancer has evolved to include patients with a spectrum of diseases."	2.39	Hormone-refractory (D3) prostate cancer: refining the concept. ( Kelly, WK; Scher, HI; Steineck, G, 1995)
"Hematologic toxicity (HT) is a joint adverse event after CAR-T cells infusion."	1.91	Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy. ( Bai, X; Guo, R; Li, Q; Lu, W; Lyu, H; Meng, J; Pu, Y; Wang, J; Xiao, X; Yuan, T; Zhang, M; Zhao, M, 2023)
"Advances in the treatment of myasthenia gravis (MG) have improved quality of life and prognosis for the majority of patients."	1.91	A series of patients with refractory myasthenia gravis. ( Díaz-Maroto, I; Garcia-Garcia, J; Martínez-Martín, A; Pardal-Fernández, JM; Segura, T, 2023)
"Gastrosplenic fistula is a rare and potentially fatal clinical entity unknown to most healthcare providers."	1.72	Successful multidisciplinary management of an asymptomatic gastrosplenic fistula in a diffuse large B cell lymphoma patient. ( Assane, C; Malo, FC; Mansouri, S, 2022)
"EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases."	1.72	EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. ( Bastos Oreiro, M; Buño, I; Carbonell, D; Chicano, M; Díaz Crespo, FJ; Diez Martín, JL; Kwon, M; Martín Rojas, R; Martínez-Laperche, C; Menárguez, J; Muñiz, P; Sanz-Villanueva, L; Suárez-González, J, 2022)
"The prognosis of childhood acute lymphoblastic leukemia (ALL) is optimistic with a 5-year event-free survival (EFS) rate of 70-85%."	1.62	Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. ( Chen, HQ; Fang, JP; Li, CG; Li, CK; Li, JQ; Li, XY; Lin, YD; Liu, RY; Luo, XQ; Sun, X; Sun, XF; Wu, XD; Xu, HG, 2021)
"The association between Takayasu's arteritis and membranous nephropathy is uncommon."	1.62	Takayasu's arteritis and secondary membranous nephropathy: an exceptional association. ( Enos, D; Hernandez, M; Labarca, G; Mendez, GP, 2021)
"Pyoderma is a disease of exclusion, but it has many variants, including ulcerative, bullous, and pustular forms."	1.62	An Unusual Presentation of Blastomycosis-Like Pyoderma Gangrenosum. ( Gordon, D; Lynn, A; Simman, R; Steven, M, 2021)
" Only systemic corticosteroids have consistently proven successful in suppressing the rash; however, the response is often only partial, and symptoms tend to recur as the dosage is tapered."	1.56	Eosinophilic dermatosis of hematologic malignancy effectively controlled with omalizumab maintenance therapy. ( Gates, G; Lor, M; Yu, Y, 2020)
"Thalidomide is a medication with strong anti-inflammatory, immunomodulatory, antiangiogenic, and sedative properties."	1.56	Thalidomide as a potential adjuvant treatment for paraneoplastic pemphigus: A single-center experience. ( Pan, M; Wang, J; Zhang, Y, 2020)
"To analyze the efficacy of rituximab combined with CHOP/EPOCH regimen for treatment of diffuse large B-cell lymphoma（DLBCL） patients, and to explore the high risk factors of refractory and relapsed patients."	1.56	[Analysis of Relevant Factors of Refractory and Relapse DLBCL Treated by Rituximab Combined with CHOP/EPOCH Regimen]. ( Chen, BA; Gao, C; Gu, Y; Wu, X; Zhang, J, 2020)
"Children with acute lymphoblastic leukemia (ALL) in low-income countries have disproportionately lower cure rates than those in high-income countries."	1.48	Outcomes of Low-Intensity Treatment of Acute Lymphoblastic Leukemia at Butaro Cancer Center of Excellence in Rwanda. ( Driscoll, C; Elmore, S; Fehr, AE; Gilbert, UD; Hategekimana, V; Larrabee, K; Lehmann, L; May, L; Moore, M; Mpunga, T; Muhayimana, C; Rubagumya, F; Shulman, LN; Shyirambere, C; Uwizeye, FR; Xu, MJ, 2018)
"Immune-related pancreatitis is a rare type of nivolumab-induced irAE that shows no significant changes on radiologic imaging, except for a swollen pancreas on CT, and can be suppressed using high-dose prednisone."	1.43	Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. ( Ikeuchi, K; Okuma, Y; Tabata, T, 2016)
"Initial spinal cord compression (ISCC) in B-cell non-Hodgkin lymphoma (NHL) is rarely present at diagnosis."	1.42	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. ( Amorim, S; Brice, P; Brière, J; Coiffier, B; de Kerviler, E; Dupuis, J; Filliatre, L; Fleury, I; Mazari, MA; Mounier, N; Thieblemont, C; Tilly, H, 2015)
"The third plasmacytoma was accompanied by progressive cervical pain and swallow dysfunction."	1.42	Recurrent extramedullary plasmacytoma in asymptomatic multiple myeloma: a case report. ( Schols, SE; Tick, LL, 2015)
"Twenty percent of patients with follicular lymphoma (FL) experience progression of disease (POD) within 2 years of initial chemoimmunotherapy."	1.42	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. ( Byrtek, M; Casulo, C; Cerhan, JR; Dawson, KL; Farber, CM; Flowers, CR; Friedberg, JW; Hainsworth, JD; Link, BK; Maurer, MJ; Zelenetz, AD; Zhou, X, 2015)
"Follicular lymphoma is a clinically and genetically heterogeneous disease, but the prognostic value of somatic mutations has not been systematically assessed."	1.42	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. ( Connors, JM; Dreyling, M; Ducar, M; Ennishi, D; Feller, AC; Gascoyne, RD; Hansmann, ML; Hiddemann, W; Horn, H; Hoster, E; Hother, C; Jurinovic, V; Klapper, W; Kopp, N; Kridel, R; Leich, E; Moccia, AA; Möller, P; Mottok, A; Murakami, M; Neuberg, D; Ott, G; Pastore, A; Pott, C; Rosenwald, A; Sehn, LH; Shulha, HP; Staiger, AM; Stein, H; Sunkavalli, A; Szczepanowski, M; Unterhalt, M; Van Hummelen, P; Weigert, O; Weinstock, DM, 2015)
"To investigate the efficacy and safety of Rituximab combined with second line regimen for treatment of relapsed and refractory Hodgkin lymphoma."	1.42	[Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients]. ( Li, H; Liu, H; Qiu, L; Xiong, W; Yi, S; Zou, D, 2015)
"We present the case of a patient with malignant lymphoma resulting from chronic pyothorax after artificial pneumothorax for pulmonary tuberculosis."	1.40	Pyothorax-associated lymphoma: complete remission achieved by chemotherapy alone. ( Iwazaki, M; Kuwahira, I; Masuda, R; Nakagawa, T; Nakamura, N; Nakano, K; Nakano, T, 2014)
"Radiation therapy of follicular lymphoma has showed consistent results, which demonstrated by 100% of 5-year tumor-specific survival in the whole group, 100% disease-free survival in patients with stage II, the lack of recurrence in the irradiation fields."	1.39	[Current technologies in radiotherapy for non-Hodgkin lymphomas]. ( Vinogradova, IuN, 2013)
"Differences between Hodgkin's lymphoma (HL) patients in China and Western countries are known to exist, but data on Chinese patients with HL are limited."	1.38	Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites. ( Huang, JJ; Jiang, WQ; Li, ZM; Xia, Y; Zhu, YJ, 2012)
"Thyroid MALT lymphoma is an extremely rare malignancy believed to arise against a background of Hashimoto's thyroiditis."	1.37	Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma. ( Ishikura, K; Iwaki, N; Kahara, T; Kaya, H; Kurokawa, T; Usuda, R; Yoshida, T, 2011)
"The risk of infection with Pneumocystis jirovecii pneumonia (PCP) in patients undergoing chemotherapy is closely related to the intensity of corticosteroid exposure."	1.36	High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. ( Filshie, R; Kamel, S; Lee, N; Nandurkar, H; O'Connor, S; Tam, CS, 2010)
"The risk of skin cancer is highly increased in kidney-transplant recipients (KTR), but the risk of subsequent skin cancers is less well studied."	1.36	Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. ( Bavinck, JN; Claas, FH; de Fijter, JW; Edelbroek, JR; Haasnoot, GW; Willemze, R; Wisgerhof, HC, 2010)
"Actinomycin D was administered at a median dosage of 0."	1.35	Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006). ( Bannink, EO; Hauptman, JG; Mullins, MN; Obradovich, JE; Sauerbrey, ML, 2008)
"Overt hyperglycemia was seen in 56 (34%) patients."	1.35	Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. ( Haymond, MW; Margolin, JF; McKay, SV; Okcu, MF; Sonabend, RY; Yan, J, 2009)
"We retrospectively estimated the minimal residual disease in the bone marrow (BM) and the testis by detection of clone-specific T-cell receptor rearrangement of leukemic cells."	1.35	Detection of submicroscopic disease in the bone marrow and unaffected testis of a child with T-cell acute lymphoblastic leukemia who experienced "isolated" testicular relapse. ( Arima, K; Hasegawa, D; Hori, T; Hosoya, R; Imamura, T; Kato, I; Kitagawa, Y; Manabe, A; Ogawa, C; Takahashi, H; Takusagawa, A; Tsurusawa, M, 2009)
"Follicular lymphoma is the second most common lymphoma throughout the world."	1.35	Meningeal relapse by follicular lymphoma as a single mass. ( Fernández Zubillaga, A; González-Barón, M; Moreno García, V; Redondo, A, 2008)
"Cure rates of Hodgkin's disease (HD) with chemotherapy and/or radiotherapy are high."	1.34	[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. ( Al-Ali, HK; Niederwieser, D; Wittekind, C, 2007)
"The treatment strategies of Hodgkin's lymphoma (HL) are different according to clinical stage and risk factors, yet the optimal treatment strategy remains unclear."	1.34	[Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases]. ( Hu, DS; Hu, S; Song, QB; Tan, WY; Wei, L; Zeng, FY; Zhou, LQ, 2007)
"Two of the patients died of disease progression."	1.33	Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. ( Ishikura, S; Kitadai, Y; Kobayashi, Y; Matsuno, Y; Mera, K; Nakamura, S; Ochiai, A; Oda, I; Ohtsu, A; Suzumiya, J; Tobinai, K; Yokoi, T; Yoshino, T, 2006)
"Adult T-cell leukemia/lymphoma (ATLL) is a malignant proliferation of mature helper T lymphocytes,(1) and is caused by human T-lymphotropic virus type I (HTLV-I);(2) an HTLV-I infection endemic in the Caribbean, south-western Japan, South America and Africa."	1.33	Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma. ( Almeida, FA; Chiba, AK; Colleoni, GW; Fernandes, MA; Michalany, NS; Petri, V; Pombo-de-Oliveira, MS; Sakamoto, FH; Teixeira, SP; Yamamoto, M, 2006)
"Records of 75 patients with aggressive B-NHL,received infusions of 375 mg/m(2) of rituximab combined with or without chemotherapy in our center,have been retrospectively analyzed."	1.32	[Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. ( Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Lin, TY; Sun, XF; Xia, ZJ; Zhang, HY; Zhang, L, 2004)
"T-cell lymphoblastic lymphoma in childhood and adolescence is an aggressive malignant disease with higher mortality."	1.32	[Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]. ( Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Liu, DG; Sun, XF; Xia, Y; Xia, ZJ; Zhang, L; Zhen, ZJ; Zhou, ZM, 2004)
"DNA aneuploidy was statistically significant (P < 0."	1.31	DNA flow cytometry of non-Hodgkin's lymphomas: correlation with cytologic grade and clinical relapse. ( Dey, P; Gupta, SK; Saikia, UN; Vohra, H, 2000)
" Despite prompt initiation of antimycotic therapy the outcome was fatal; dosage of conventional and liposomal amphotericin B was limited due to treatment-related toxicities."	1.31	A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation. ( Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K, 2001)
"Sixteen patients with Hodgkin's disease were treated with MOPP/ABVD and filgrastim support between January 1992 and March 1994."	1.30	G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. ( Gustavsson, A, 1997)
"The International Breast Cancer Study Group (IBCSG) prospectively explored the efficacy of retreatment for patients upon relapse using the same therapy administered during the adjuvant programme."	1.30	Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. ( Castiglione-Gertsch, M; Coates, A; Collins, J; Gelber, RD; Goldhirsch, A; Gudgeon, A; Hacking, A; Isley, M; Lindtner, J; Rudenstam, CM; Senn, HJ; Tattersall, M, 1997)
"Optimal treatment for Hodgkin's disease during childhood is unknown."	1.30	Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy. ( Farah, RA; Geara, F; Hajjar, T; Khogali, M; Muwakkit, S; Nabbout, B; Shabb, NS, 1999)
"In patients with advanced Hodgkin's disease (HD), the alternation of MOPP with ABVD or hybrid MOPP/ABVD are associated with a high CR rate and a high probability of 5-year survival."	1.29	Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease. ( Aversa, S; Bianco, A; Chiarion Sileni, V; Fiorentino, MV; Mazzarotto, R; Pappagallo, GL; Salvagno, L; Scarzello, G; Sorarù, M; Sotti, G, 1995)
"Two cases of malignant schwannoma are reported 13 and 15 years following combined modality treatment for Hodgkin's disease."	1.29	Malignant schwannoma following treatment for Hodgkin's disease. ( Bridges, LR; Cartwright, SC; Dodwell, DJ; Fisher, PM; Stone, J, 1994)
"Because thymoma is a chemosensitive tumor and frequently recurs in patients with Stage II or greater disease, chemotherapy carries a potential survival benefit and should be incorporated into the multimodality approach to prolong disease-free survival."	1.29	Thymoma. A retrospective study of 87 cases. ( Cox, JD; Hong, WK; Komaki, R; Lee, JS; Park, HS; Pollack, A; Putnam, JB; Shin, DM, 1994)
"20 patients in early stages (I-IIB) Hodgkin's disease were treated with smaller than commonly used doses of cytostatics and radiation."	1.29	[Preliminary results of conservative combination radiotherapy and chemotherapy in early stages of Hodgkin's disease]. ( Dubowik, R; Gabryś, K; Urbaniak-Kujda, D, 1996)
"Stage II patients with breast carcinoma who had undergone lumpectomy."	1.28	Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. A pilot trial. ( Allen, S; Bosworth, H; Budman, D; Lehrman, D; Lichtman, SM; Schulman, P; Vinciguerra, V; Weiselberg, L; Weiss, R, 1991)
"Fifty-three patients with advanced Hodgkin's disease, most of them previously treated, received 8 to 16 courses of modified MOPP regimens (nitrogen mustard replaced by trichlormethine in arm A, with addition of vinblastine to the 4-drug regimen in arm B, and alternation of three drugs--trichlormethine, vincristine, and prednisone--with probably non-cross resistant two drugs--vinblastine and procarbazine in arm C)."	1.28	Treatment of advanced Hodgkin's disease with modified MOPP regimens. A long-term observation. ( Bohunický, L; Cerný, V; Gyárfás, J; Koza, I; Mardiak, J; Svancárová, L, 1989)
"Although most patients with Hodgkin's disease refractory to MOPP treatment will respond to either ABVD or B-CAVe chemotherapy, subsequent long-term disease-free survival is unusual."	1.27	Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. ( Harker, WG; Kushlan, P; Rosenberg, SA, 1984)
"In 7 transplant recipients with skin cancer, the mean SCE frequency was 14."	1.27	Sister chromatid exchange in lymphocytes from renal transplant recipients with and without cancer. ( Kelly, GE; Sheil, AG, 1983)
"Many children with acute lymphoblastic leukemia (ALL) develop a marrow relapse during or shortly following initial continuation chemotherapy."	1.27	Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. ( Boyett, JM; Buchanan, GR; Chauvenet, AR; Crist, WM; Rivera, GK; Vietti, TJ, 1988)
"The neurofibroma was congenital and extensively involved the soft tissue and bone of the face and neck."	1.27	Malignant lymphoma arising in a large congenital neurofibroma of the head and neck. Report of a case. ( Foucar, E; Gooding, RA; Palmer, CH; Radi, MJ, 1988)
" Chemotherapy consisted of two cycles of CF (cyclophosphamide at a dosage of 100 mg/m2 orally on days 1-14+5-fluorouracil at 600 mg/m2 iv on days 1 and 8) during concurrent radiotherapy, followed by six cycles of CMFP (same CF dosages+methotrexate at 40 mg/m2 iv on days 1 and 8+prednisone at 40 mg/m2 orally on days 1-14)."	1.27	Integration of full-dose adjuvant chemotherapy with definitive radiotherapy for primary breast cancer: four-year update. ( Fowble, BL; Fox, KR; Glick, JH; Glover, DJ; Goodman, RL; Haller, DG; Hurwitz, S; Mackie, JA; Rosato, EF; Weiler, C, 1988)
"Thymic hyperplasia is a poorly understood, apparently benign process that may be confused with recurrent lymphoma."	1.27	Thymic hyperplasia masquerading as recurrent Hodgkin's disease: case report and review of the literature. ( Edington, H; Longo, DL; Pass, H; Roth, JA; Salwitz, J, 1986)
", CAF (CPA + ADM + 5-FU), and AC (ADM + CPA) are well known, but the dosage and administration schedule differ somewhat with the researcher."	1.27	[Chemotherapy for recurrent breast carcinoma]. ( Taguchi, T, 1985)
"In the group of high-grade malignant lymphomas there were 39% complete remission, 37% partial remission, and 24% without response."	1.26	[Results of chemotherapy with cyclophosphamide, vincristine, methotrexate and prednisone in recurring or disseminated non-Hodgkin lymphomas in the University of Kiel Radiology Clinic]. ( Liffers, R, 1981)
"Cases of disintegrating pulmonary metastases are presented."	1.26	[Confluent pulmonary deposits from carcinoma of the breast under cytostatic therapy (author's transl)]. ( Blechschmidt, CM; Schermuly, W, 1976)
"Patients with diffuse histiocytic lymphoma who achieved a histologically proven complete remission after 6 months of treatment without maintenance have remained disease-free whereas those with nodular poorly differentiated lymphocytic and diffuse well-differentiated lymphocytic lymphomas have demonstrated a pattern of continuous late recurrence."	1.25	Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. ( Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Young, RC, 1975)
"Although breast cancer presents as localized disease and is treated with local modalities, i."	1.25	Chemotherapy in the treatment strategy of breast cancer. ( Carbone, PP, 1975)
" Radical excision of the tumor, if possible, and the remaining thymus, high dosage alternate day prednisone, and radiation therapy, if indicated, seem the treatments of choice."	1.25	Myasthenia gravis and invasive thymoma: a 20-year experience. ( Brown, WJ; Goldman, AJ; Herrmann, C; Keesey, JC; Mulder, DG, 1975)

Research

Studies (497)

Authors

Clinical Trials (28)

Trial Overview

Trial Outcomes

Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)

Timeframe	Studies, this research(%)	All Research%
pre-1990	107 (21.53)	18.7374
1990's	76 (15.29)	18.2507
2000's	93 (18.71)	29.6817
2010's	132 (26.56)	24.3611
2020's	89 (17.91)	2.80

Authors	Studies
Cox, MC	2
Banchi, M	1
Pelliccia, S	2
Di Napoli, A	2
Marcheselli, L	4
Patti, C	4
Anticoli Borza, P	1
Battistini, R	2
Di Gregorio, F	1
Orlandi, P	1
Bocci, G	2
Arcari, A	2
Borza, PA	1
Casaroli, I	1
di Landro, F	1
Fabbri, F	1
Caridi, M	1
Tafuri, A	1
Musuraca, G	2
Ulu, BU	1
Yiğenoğlu, TN	1
Başcı, S	1
Bakırtaş, M	1
Şahin, D	1
Darçın, T	1
Yaman, S	1
Bozan, E	1
Seçilmiş, S	1
Candır, BA	1
Yıldız, J	1
İskender, D	1
Baysal, NA	1
Çakar, MK	1
Dal, MS	1
Altuntaş, F	1
Spetsieris, N	1
Boukovala, M	1
Alafis, I	1
Davis, J	1
Zurita, A	1
Wang, X	3
Tu, SM	1
Chapin, BF	1
Aparicio, A	1
Corn, P	1
Wang, J	6
Subudhi, SK	1
Araujo, J	1
Papadopoulos, J	1
Pruitt, L	1
Weldon, JA	1
Logothetis, CJ	2
Efstathiou, E	1
Icard, C	1
Mocquot, P	1
Nogaro, JC	1
Despas, F	1
Gauthier, M	1
Ho, G	1
Tan, C	1
de Mel, S	1
Poon, L	1
Chan, EHL	1
Lee, J	1
Liu, X	2
Chng, WJ	1
Chee, YL	1
Soon, YY	1
Jeyasekharan, AD	4
Reiss, SN	1
Yerram, P	1
Modelevsky, L	1
Grommes, C	1
Parikh, RR	1
Kelly, KM	3
Hodgson, DC	1
Hoppe, BS	3
McCarten, KM	2
Karolczuk, K	1
Pei, Q	3
Wu, Y	3
Cho, SY	1
Schwartz, C	1
Cole, PD	1
Roberts, K	1
Wilson, MR	1
Eyre, TA	2
Kirkwood, AA	2
Wong Doo, N	1
Soussain, C	1
Choquet, S	1
Martinez-Calle, N	1
Preston, G	1
Ahearne, M	1
Schorb, E	1
Moles-Moreau, MP	1
Ku, M	1
Rusconi, C	1
Khwaja, J	1
Narkhede, M	1
Lewis, KL	2
Calimeri, T	2
Durot, E	1
Renaud, L	2
Øvlisen, AK	1
McIlroy, G	1
Ebsworth, TJ	1
Elliot, J	1
Santarsieri, A	1
Ricard, L	1
Shah, N	1
Liu, Q	2
Zayac, AS	1
Vassallo, F	1
Lebras, L	1
Roulin, L	1
Lombion, N	1
Manos, K	2
Fernandez, R	1
Hamad, N	1
Lopez-Garcia, A	1
O'Mahony, D	1
Gounder, P	1
Forgeard, N	1
Lees, C	1
Agbetiafa, K	1
Strüßmann, T	1
Htut, TW	1
Clavert, A	1
Scott, H	1
Guidetti, A	1
Barlow, BR	1
Tchernonog, E	1
Smith, J	1
Miall, F	1
Fox, CP	1
Cheah, CY	3
El Galaly, TC	1
Ferreri, AJM	2
Cwynarski, K	1
McKay, P	1
Cahill, KE	1
Smith, SM	2
Mansouri, S	1
Assane, C	1
Malo, FC	1
Savage, KJ	6
Horwitz, SM	2
Advani, R	1
Christensen, JH	1
Domingo-Domenech, E	2
Rossi, G	1
Morschhauser, F	4
Alpdogan, O	1
Suh, C	5
Tobinai, K	5
Shustov, A	1
Trneny, M	1
Yuen, S	1
Zinzani, PL	2
Trümper, L	2
Ilidge, T	1
O'Connor, OA	1
Pro, B	3
Miao, H	1
Bunn, V	1
Fenton, K	1
Fanale, M	1
Puhlmann, M	1
Iyer, S	1
Ngu, H	1
Takiar, R	1
Phillips, T	1
Okosun, J	1
Sehn, LH	7
Özbalak, M	1
Güzel Mastanzade, M	1
Özlük, Ö	1
Tiryaki, TO	1
Erdem, S	1
Özbalak, EP	1
Elverdi, T	1
Yönal Hindilerden, İ	1
Altay, AY	1
Yeğen, G	1
Eşkazan, AE	1
Ar, MC	1
Yenerel, MN	1
Soysal, T	1
Nalçacı, M	1
Ferhanoğlu, B	1
Kalayoğlu Beşışık, S	1
Camus, V	1
Belot, A	1
Oberic, L	1
Sibon, D	1
Ghesquières, H	1
Thieblemont, C	3
Fruchart, C	1
Casasnovas, O	2
Michot, JM	1
Molina, TJ	1
Bosly, A	1
Joubert, C	1
Haioun, C	2
Nicolas-Virelizier, E	1
Feugier, P	1
Fitoussi, O	2
Delarue, R	1
Tilly, H	3
Parekh, A	1
Keller, FG	2
Kessel, S	1
Cho, S	2
Castellino, SM	2
Constine, LS	2
Schwartz, CL	1
Hodgson, D	2
Edina, BC	1
Rinaldi, I	1
Othman, T	1
Penaloza, J	1
Zhang, S	1
Daniel, CE	1
Gaut, D	1
Oliai, C	1
Brem, EA	1
Baweja, A	1
Ly, J	1
Reid, J	1
Pinter-Brown, L	1
Lee, M	1
Abdulhaq, H	1
Tuscano, J	1
Jessa, R	1
Chien, N	1
Villa, D	3
Freeman, CL	1
Slack, GW	1
Scott, DW	1
Song, KW	1
Gerrie, AS	1
Martínez-Laperche, C	1
Sanz-Villanueva, L	1
Díaz Crespo, FJ	1
Muñiz, P	1
Martín Rojas, R	1
Carbonell, D	1
Chicano, M	1
Suárez-González, J	1
Menárguez, J	1
Kwon, M	1
Diez Martín, JL	1
Buño, I	1
Bastos Oreiro, M	1
Meeuwes, FO	1
Brink, M	1
van der Poel, MWM	1
Kersten, MJ	1
Wondergem, M	1
Mutsaers, PGNJ	1
Böhmer, L	1
Woei-A-Jin, S	1
Visser, O	1
Oostvogels, R	1
Jansen, PM	1
Diepstra, A	2
Snijders, TJF	1
Plattel, WJ	1
Huls, GA	1
Vermaat, JSP	1
Nijland, M	2
Zhang, N	1
Xu, D	1
Liu, B	1
Shi, X	1
Xie, X	1
Wang, Z	2
Zhang, J	3
Gan, J	1
Parsons, SK	1
McCarten, K	1
Horton, T	1
Punnett, A	1
Dave, H	1
Henderson, TO	1
Charpentier, AM	1
Lian, K	3
Zhang, QH	3
Hou, SL	3
Li, L	4
Lim, SK	3
Peng, CC	3
Low, S	3
Vijay, V	3
Budiman, A	3
Phang, BH	3
Lim, JQ	3
Lim, ST	3
Ong, CK	3
Tan, SM	3
Li, Y	4
Altmann, B	1
Frontzek, F	1
Chartier, L	1
Ketterer, N	1
Récher, C	1
Poeschel, V	1
Held, G	1
Glass, B	2
Mounier, N	2
Rosenwald, A	2
Ott, G	2
Lenz, G	1
Molina, T	1
Ziepert, M	1
Schmitz, N	3
Tabanelli, V	1
Merli, F	1
Merli, M	2
Balzarotti, M	1
Zilioli, VR	1
Fabbri, A	1
Cavallo, F	1
Casaluci, GM	1
Tucci, A	1
Puccini, B	1
Pennese, E	2
Di Rocco, A	1
Zanni, M	2
Flenghi, L	1
Gini, G	2
Sartori, R	1
Chiappella, A	1
Usai, SV	2
Tani, M	1
Marino, D	1
Arcaini, L	1
Vallisa, D	2
Spina, M	1
Joly, P	1
Lafon, A	1
Houivet, E	1
Donnadieu, N	1
Richard, MA	1
Dupuy, A	1
Delaporte, E	1
Bernard, P	1
Machet, L	1
Tosti, A	1
Del Marmol, V	1
Grimalt, R	1
de Viragh, PA	1
Benichou, J	1
Chosidow, O	1
Assouly, P	1
Reygagne, P	1
Chong, G	1
Keane, C	1
Lee, ST	1
Smith, C	1
Churilov, L	1
McKendrick, J	1
Renwick, W	1
Blombery, P	1
Burgess, M	1
Nelson, NE	1
Fancourt, T	1
Hawking, J	1
Lin, W	1
Scott, AM	1
Barraclough, A	1
Wight, J	1
Grigg, A	1
Fong, CY	1
Hawkes, EA	2
Yu, L	1
Jiang, X	1
Ding, K	1
Zhang, M	2
Lyu, H	1
Guo, R	1
Xiao, X	2
Bai, X	1
Pu, Y	1
Meng, J	1
Li, Q	2
Yuan, T	1
Lu, W	1
Zhao, M	1
Komminoth, M	1
Donath, MY	1
Hepprich, M	1
Schuetz, P	1
Blum, CA	1
Mueller, B	1
Reny, JL	1
Gosselin, P	1
Breville, G	1
Brändle, M	1
Henzen, C	1
Leuppi, JD	1
Kistler, AD	1
Thurnheer, R	1
Beuschlein, F	1
Rudofsky, G	1
Aeberli, D	1
Villiger, PM	1
Böhm, S	1
Chifu, I	1
Fassnacht, M	1
Meyer, G	1
Bojunga, J	1
Cattaneo, M	1
Sluka, C	1
Schneider, H	1
Rutishauser, J	1
Garcia-Garcia, J	1
Díaz-Maroto, I	1
Martínez-Martín, A	1
Pardal-Fernández, JM	1
Segura, T	1
Ibrahim, EM	1
Refat, S	1
El-Ashwah, S	1
Fahmi, MW	1
Ibrahiem, AT	1
Xu, Y	2
Liu, S	1
Zeng, X	1
Wu, Q	1
Chen, Y	2
He, C	1
Zhai, Q	1
Zhang, B	1
Gao, J	1
Zimmerman, K	1
Walsh, KA	1
Ferrari, JT	1
Keuler, NS	1
Atherton, MJ	1
Lenz, JA	1
Ogura, M	3
Yamamoto, K	1
Morishima, Y	1
Wakabayashi, M	1
Ando, K	1
Uike, N	1
Kurosawa, M	1
Gomyo, H	1
Taniwaki, M	1
Nosaka, K	1
Tsukamoto, N	2
Shimoyama, T	1
Fukuhara, N	2
Yakushijin, Y	1
Ohnishi, K	1
Miyazaki, K	4
Kameoka, Y	1
Takayama, N	1
Hanamura, I	1
Kobayashi, H	1
Usuki, K	1
Kobayashi, N	1
Ohyashiki, K	1
Utsumi, T	1
Kumagai, K	1
Maruyama, D	1
Ohmachi, K	1
Matsuno, Y	3
Nakamura, S	5
Hotta, T	1
Tsukasaki, K	1
Nagai, H	2
Zhou, N	1
Choi, J	1
Grothusen, G	1
Kim, BJ	1
Ren, D	1
Cao, Z	1
Liu, Y	3
Inamdar, A	1
Beer, T	1
Tang, HY	1
Perkey, E	1
Maillard, I	1
Bonasio, R	1
Shi, J	1
Ruella, M	1
Wan, L	1
Busino, L	1
Nizzoli, ME	1
Manni, M	1
Ghiggi, C	1
Pulsoni, A	2
Califano, C	1
Bari, A	1
Massaia, M	1
Conconi, A	1
Musto, P	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas[NCT01777152]	Phase 3	452 participants (Actual)	Interventional	2013-01-31	Completed
A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease[NCT00302003]	Phase 3	287 participants (Actual)	Interventional	2006-02-28	Completed
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults[NCT02166463]	Phase 3	600 participants (Actual)	Interventional	2015-03-19	Active, not recruiting
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With [NCT00790036]	Phase 3	742 participants (Actual)	Interventional	2009-07-24	Completed
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia[NCT04554459]	Phase 2	32 participants (Anticipated)	Interventional	2021-02-16	Active, not recruiting
An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma[NCT00825149]	Phase 1	137 participants (Actual)	Interventional	2009-02-28	Completed
The H10 EORTC/GELA/IIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage I/II Hodgkin's Lymphoma[NCT00433433]	Phase 3	1,952 participants (Actual)	Interventional	2006-10-31	Active, not recruiting
Phase 1/2 Study of Decitabine Alone and/or in Combination With Chemotherapy and/or Cytokine Induced Killer Cell Transfusion in Patients With Relapsed or Refractory Solid Tumors and B Cell Lymphomas[NCT01799083]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Addition of Decitabine to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Phase 2-3, Open-label, Randomised Controlled Trial[NCT02159820]	Phase 2/Phase 3	500 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial[NCT03336073]	Phase 2	199 participants (Actual)	Interventional	2017-12-18	Active, not recruiting
A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma[NCT00513955]	Phase 2	50 participants (Actual)	Interventional	2006-06-30	Completed
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111]	Phase 3	501 participants (Actual)	Interventional	2000-07-08	Completed
Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647]	Phase 2	4 participants (Actual)	Interventional	2020-11-23	Completed
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry[NCT04587388]		500 participants (Anticipated)	Observational [Patient Registry]	2019-05-22	Recruiting
Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone (R2-GOD) in Treatment of Relapse/Refractory DLBCL:A Phase I Study[NCT03795571]	Phase 1	12 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Short Chemo Radiotherapy in Follicular Lymphoma Trial of 90Y Ibritumomab Tiuxetan (ZevalinTM) as Therapy for First and Second Relapse in Follicular Lymphoma[NCT00637832]	Phase 2	1 participants (Actual)	Interventional	2008-04-01	Terminated (stopped due to no information)
AN OPEN-LABEL, PHASE 1 STUDY OF R-CVP OR R-GDP IN COMBINATION WITH INOTUZUMAB OZOGAMICIN IN SUBJECTS WITH CD22-POSTIVE NON-HODGKIN'S LYMPHOMA[NCT01055496]	Phase 1	103 participants (Actual)	Interventional	2010-03-31	Completed
Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size[NCT00332969]	Phase 2	25 participants (Actual)	Interventional	2005-09-30	Completed
Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy[NCT01486043]		4 participants (Actual)	Interventional	2011-12-31	Terminated (stopped due to The research project was terminated due to lower than projected patient recruitment within the period of time allowed for the study.)
A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma[NCT00141648]		70 participants (Actual)	Interventional	2000-09-30	Completed
National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation[NCT02340936]	Phase 1/Phase 2	53 participants (Actual)	Interventional	2011-01-31	Completed
A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma[NCT00389818]	Phase 2	43 participants (Actual)	Interventional	2007-01-31	Completed
Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma[NCT03293173]	Phase 2	120 participants (Anticipated)	Interventional	2017-08-04	Recruiting
CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) ≥ 2. A Phase II Study[NCT01502982]	Phase 2	160 participants (Actual)	Interventional	2004-11-30	Completed
A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma[NCT02008006]	Phase 2	21 participants (Actual)	Interventional	2014-07-09	Terminated (stopped due to Insufficient recruitment and unavailability of the treatment)
Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II, Single-arm, Open-label, Muti-center Study[NCT02879526]	Phase 2	45 participants (Anticipated)	Interventional	2016-08-31	Recruiting
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2012-06-30	Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.)
Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial[NCT00001250]	Phase 2	130 participants	Interventional	1989-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma. (NCT01777152)
Timeframe: Up to 8.34 months

Objective Response Rate (ORR) Per IRF at End of Treatment

Intervention	Participants (Count of Participants)
A+CHP	153
CHOP	126

The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma. (NCT01777152)
Timeframe: Up to 8.34 months

Overall Survival (OS)

Intervention	Participants (Count of Participants)
A+CHP	188
CHOP	163

The time from randomization to death due to any cause. (NCT01777152)
Timeframe: Up to 90 months

Progression-free Survival Per Independent Review Facility (IRF)

Intervention	Months (Median)
A+CHP	NA
CHOP	NA

The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first. (NCT01777152)
Timeframe: Up to 60 months

Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)

Intervention	months (Median)
A+CHP	48.20
CHOP	20.80

Incidence of Adverse Events (AEs)

Intervention	months (Median)
A+CHP	55.66
CHOP	32.03

Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment. (NCT01777152)
Timeframe: Up to 8.28 months

Incidence of Laboratory Abnormalities

Intervention	Participants (Count of Participants)
	Any treatment-emergent AE	Blinded study treatment-related AE	CHP treatment-related AE	Any serious adverse event (SAE)	Blinded study treatment-related SAE	CHP treatment-related SAE	Treatment discontinuations due to AE	Treatment discontinuations due to blinded study treatment-related AE	Treatment discontinuations due to CHP treatment-related AE
A+CHP	221	201	198	87	58	62	14	10	8
CHOP	221	193	205	87	45	53	15	10	7

Number of participants who experienced a Grade 3 or higher laboratory toxicity. (NCT01777152)
Timeframe: Up to 8.28 months

Event Free Survival (EFS)

Intervention	Participants (Count of Participants)
	Any Chemistry Test	Alanine Aminotransferase High	Albumin Low	Alkaline Phosphatase High	Calcium Low	Glucose High	Phosphate Low	Potassium High	Potassium Low	Sodium High	Sodium Low	Urate High	Any Hematology Test	Absolute Neutrophil Count Low	Hemoglobin High	Hemoglobin Low	Leukocytes Low	Lymphocytes High	Lymphocytes Low	Neutrophils Low	Platelets Low
A+CHP	25	3	2	1	1	8	4	0	3	1	4	5	68	17	1	9	12	0	52	17	1
CHOP	23	1	3	0	1	6	3	2	2	0	6	2	78	19	0	13	21	1	61	19	1

Survival is defined as the minimum time from study entry to a relapse of any kind, death from any cause, or occurrence of a second malignant neoplasm. Patients without report of such events where censored at last contact. This will be used to compute event free survival (EFS). (NCT00302003)
Timeframe: At 60 months

Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).

Intervention	Probability of survival (Number)
Group 1	0.79

Survival is defined as the minimum time from study entry to requirement for additional chemotherapy and IFRT for retrieval, occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact. Patients who achieve less than CR after 3 cycles of AV-PC will require IFRT and hence will satisfy this definition at the time of response evaluation. Patients who achieve a CR but who relapse will receive addition chemotherapy and IFRT or intense retrieval and hence will satisfy this definition at the time of the first relapse of Hodgkin disease. This endpoint will be used to compute event free survival without receiving radiation therapy (EFSnoRT). (NCT00302003)
Timeframe: At 60 months

Intensive Therapy Free Survival (ITFS).

Intervention	Probability of survival (Number)
Group 1	0.49

Survival is defined as the minimum time from study entry to a relapse of higher risk at any time, any relapse following treatment with protocol mandated IFRT, death from any cause, or the occurrence of a second malignant neoplasm. This will be used to compute intensive therapy free survival (ITFS). Patients without report of such events where censored at last contact. This differs from traditional EFS in that relapse after AVPC* x3 therapy alone that does not place the patient in a higher risk category is not considered a treatment failure. In this definition, higher-risk relapse refers to relapse involving sites and extent of disease that place the patient in the current COG definition of intermediate or high-risk disease. If a patient with CR who experiences a LR relapse is not retreated with protocol-mandated chemotherapy and IFRT, subsequent disease relapses will nevertheless be counted in the analysis of the treatment strategy. (NCT00302003)
Timeframe: At 60 months

Overall Survival

Intervention	Probability of survival (Number)
Group 1	0.89

Survival is defined as time from study entry to death due to any cause. Patients alive at last contact where censored at last contact. (NCT00302003)
Timeframe: At 60 months

Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death

Intervention	Probability of survival (Number)
Group 1	0.99

Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle. Progression is defined as an ≥50% increase of in the product of the perpendicular diameters of any of the involved nodes or nodal masses or focal organ lesions in sites that were persistently PET positive; or recurrent PET positive lesions (Deauville 4, 5) in sites that had previously been PET negative regardless of change of size, as was the development of new PET avid measurable lesion(s) >1.5cm in any axis, or new sites of assessable disease. Relapse is defined in patients who achieved a prior CR but subsequently has an increase of ≥50% of the PPD in prior nodal or extranodal sites in a recurrently PET positive lesion(s), or the development of new measurable lesion(s) >1.5cm in any axis, or new sites of assessable disease. Second malignancy is defined based on report of a cancer that is not considered to be classic Hodgkin Lymphoma. (NCT02166463)
Timeframe: Up to 48 months after the last enrollment

Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale

Intervention	percentage of participants (Number)
Arm I (ABVE-PC)	82.5
ARM II (Bv-AVEPC)	92.1

"The percentages of patients experiencing grade 3+ peripheral neuropathy assessed by the treating clinician using the modified Balis scale. The Modified Balis scale of Pediatric Neuropathy allows clinicians to assign a score for sensory or motor neuropathy symptoms separately. Scores range from 1 to 4 with 1 being the least symptomatic state and 4 indicating a severe debility. The percentages of patients (with a score >/=3) will be compared between the 2 arms by two-sample Z test at 1-sided alpha level of 0.05." (NCT02166463)
Timeframe: From the enrollment of the patient to the time of analysis or the last follow-up; an average of 3.6 years.

Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review

Intervention	Percentage of patients (Number)
Arm I (ABVE-PC)	5.5
ARM II (Bv-AVEPC)	6.7

The percentages of patients (with available PET scan) with no SRL and no PD will be compared between the two randomized arms to see if brentuximab vedotin in the chemotherapy backbone of doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) arm has a higher rate of early response compared to doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide (ABVE-PC) arm. Two-sample Z test of proportions at 1-sided alpha level of 0.05 will be used for these comparisons. (NCT02166463)
Timeframe: After 42 days of chemotherapy

Disease-free Survival (DFS)

Intervention	Percentage of patients (Number)
Arm I (ABVE-PC)	80.7
ARM II (Bv-AVEPC)	81.2

DFS was defined as the time from date of randomization to the date of event defined as the first documented relapse of the disease or death due to any cause. Relapse was based on investigator assessment and was assigned only if: It was documented according to Cheson guidelines by an objective radiological assessment method; It was documented by a biopsy proven lymphoma including new or recurrent bone marrow involvement; A new anticancer therapy for lymphoma started with subsequent confirmation of the relapse within 4 weeks of the start of this anticancer therapy (NCT00790036)
Timeframe: From date of randomization to the date of event defined as the first documented recurrence of the disease, or death due to any cause and up to 6 years

Lymphoma-specific Survival (LSS)

Intervention	Percentage of participants (Number)
RAD001 (Everolimus)1	77.8
Placebo	77.0

LSS was defined as time from randomization to death as a result of lymphoma. (NCT00790036)
Timeframe: From randomization to death documented as a result of lymphoma up to 7 years

Overall Survival (OS)

Intervention	Percentage of participants (Number)
	2 years	3 years	4 years	5 years	6 years
Placebo	90.5	88.8	86.9	85.4	85.4
RAD001 (Everolimus)1	94.9	93.1	91.6	89.4	89.4

OS was defined as the time from date of randomization to date of death due to any cause. If the patient was not known to have died, survival was censored at the date of the last contact. (NCT00790036)
Timeframe: From date of randomization to date of death due to any cause up to around 7 years

Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)

Intervention	Percentage of participants (Number)
	2 years	3 years	4 years	5 years	6 years
Placebo	88.3	83.7	80.7	77.4	77.4
RAD001 (Everolimus)1	90.7	88.0	85.4	83.4	80.3

"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion

Continuous Complete Remission Since Week 56 Therapy.

Intervention	Percent change (Mean)
4 hr	-44
24 hr	-50

CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years

Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).

Intervention	Percentage of participants (Number)
Patients With High Risk of CNS Relapse	92.2

Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)

Overall Event-free Survival (EFS)

Intervention	pmol/1,000,000,000 cells (Mean)
4 hr	1688
24 hr	2521

EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years

Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells

Intervention	Percentage of Participants (Number)
Total Therapy	87.3

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells

Intervention	arbitrary units (Median)
	Prednisolone-sensitive cells	Prednisolone-resistant cells
Total Therapy	341.3	447.9

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Minimal Residual Disease (MRD)

Intervention	arbitrary units (Median)
	Prednisolone-sensitive cells	Prednisolone-resistant cells
Total Therapy	41.2	110.7

Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)

Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction

Intervention	participants (Number)
	Negative <0.01%	Positive >= 0.01%
Total Therapy	390	102

"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction

Number of Participants With Complete Response Rate (CR) at up to 12 Months Post MONO - Monotherapy: Ublituximab or Combotherapy: Ublituximab + Umbralisib.

Intervention	Participants (Count of Participants)
Ublituximab Only	2

"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction

Overall Response Rates (ORR) for Number of Participants

Intervention	Participants (Count of Participants)
Ublituximab Only	2
Ublituximab First, Then Ublituximab and Umbralisib	2

"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction

Kaplan-Meier Estimate of the OS in the MTD Confirmation/EE Cohorts

Intervention	Participants (Count of Participants)
Ublituximab Only	2
Ublituximab First, Then Ublituximab and Umbralisib	2

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period

Kaplan-Meier Estimate of the Overall Survival (OS) in the DE Cohorts

Intervention	Months (Median)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	NA
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	NA

Kaplan-Meier Estimate of the PFS in the MTD Confirmation/EE Cohorts

Intervention	Months (Median)
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	NA
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	NA

PFS was defined as time from date of first dose to the earlier date of progression (including symptomatic deterioration), date of death from any cause, or initiation of new anticancer therapy for the lymphoma. Participants without an event were censored at the date of the last valid tumour assessment. A valid tumour assessment visit was defined as the tumour assessment visit with OR of CR, PR, SD, or PD, but not 'Not Done' or 'Unknown'. Participants without a post-baseline tumour assessment and without a PFS event were censored on the date of first dose. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks

Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in the DE Cohorts

Intervention	Months (Median)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	14.36
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	6.14

PFS was defined as time from date of first dose to the earlier date of progression (including symptomatic deterioration), date of death from any cause, or initiation of new anticancer therapy for the lymphoma. Participants without an event were censored at the date of the last valid tumour assessment. A valid tumour assessment visit was defined as the tumour assessment visit with overall response of CR, PR, stable disease (SD), or disease progression (PD), but not 'Not Done' or 'Unknown'. Participants without a post-baseline tumour assessment and without a PFS event were censored on the date of first dose. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks

Participants Reporting DLT AEs for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 2

Intervention	Months (Median)
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	16.36
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	10.12

DLT was defined as: febrile neutropenia, Grade (Gr) 4 neutropenia ≥7 days, Gr 4 thrombocytopenia ≥7 days, Gr 3/4 thrombocytopenia associated with bleeding requiring a transfusion, Gr 3/4 non-hematologic toxicity (except alopecia) ≥7 days or treatment-related and clinically significant irrespective of duration, ≥Gr 3 QTc prolongation, Gr 4 alanine or aspartate aminotransferase, Gr 2 hyperbilirubinemia (greater than (>)1.5 x upper normal limit) >7 days, delayed recovery from a treatment-related toxicity that prevented re-dosing by >7 days, or Granulocyte-colony stimulating factor treatment during the first cycle. (NCT01055496)
Timeframe: From the first dose of study medication (Study Day 1) to the completion of the first 21-day cycle.

Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1

Intervention	Participants (Count of Participants)
Cohort 1, Arm 2	0
Cohort 2a, Arm 2	2
Cohort 2b, Arm 2	1
Cohort 3b, Arm 2	2
Cohort 4, Arm 2	0
MTD Confirmation Cohort, Arm 2	3

Percentage of Participants With a Best OR of CR or PR According to International Response Criteria for NHLs in the DE Cohorts

Intervention	Participants (Count of Participants)
Cohort 1, Arm 1	0
Cohort 2, Arm 1	0
Cohort 3, Arm 1	1
Cohort 4, Arm 1	2
MTD Confirmation Cohort, Arm 1	2

OR was evaluated according to the International Response Criteria for NHLs. CR was defined as complete disappearance of all lesions and disease-related symptoms; all nodes must have decreased to normal (≤1.5 cm in their GTD for nodes >1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as >50% decrease in the SPD of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by ≥50% in the SPD or GTD (for single nodules). With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks.

Percentage of Participants With Any Grade 3/4 Chemistry Abnormality During Therapy

Intervention	Percentage of participants (Number)
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	81.3
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	51.9

"The following parameters were analyzed for blood chemistry: blood urea nitrogen (or urea), creatinine, glucose, calcium, sodium, potassium, phosphorus, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, total bilirubin (and direct bilirubin, if total bilirubin was elevated), alkaline phosphatase, uric acid (or urate), albumin and total protein. Laboratory test results were graded using the NCI CTCAE v3.0 where CTCAE Grade 3 equals severe and CTCAE Grade 4 equals life threatening or disabling." (NCT01055496)
Timeframe: Within 3 days prior to the start of each cycle, on Day 8 of each cycle, on Day 15 of Cycles 1, 2, and 3, and the end-of-treatment visit. Each Cycle is 21 Days.

Percentage of Participants With Any Grade 3/4 Hematology Abnormality During Therapy

Intervention	Percentage of Participants (Number)
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin	21.3
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin	36.4

"The following parameters were analyzed for hematology: lymphocytes, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, monocytes, neutrophils, platelets, prothrombin international normalized ratio, prothrombin time, fibrinogen, and activated partial thromboplastin time. Laboratory test results were graded using the NCI CTCAE v3.0 where CTCAE Grade 3 equals severe and CTCAE Grade 4 equals life threatening or disabling." (NCT01055496)
Timeframe: Within 3 days prior to the start of each cycle, Day 8 of each cycle, Day 15 of Cycles 1, 2, and 3, and the end-of-treatment visit. Each Cycle is 21 Days.

Percentage of Participants With Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) According to International Response Criteria for NHLs in the MTD and EE Cohorts

Intervention	Percentage of Participants (Number)
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin	91.7
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin	96.4

OR was evaluated according to the International Response Criteria for NHLs. CR was defined as complete disappearance of all lesions and disease-related symptoms; all nodes must have decreased to normal (less than or equal to [≤]1.5 centimeters [cm] in their greatest transverse diameter (GTD) for nodes >1.5 cm before therapy) or ≤1 cm (short axis) in previously involved node; enlarged spleen prior to therapy must have regressed and be non-palpable; bone marrow lymphoma: infiltrate must have been cleared on repeat bone marrow aspirate and biopsy. PR was defined as >50% decrease in the sum of the product diameters (SPD) of up to 6 index lesions. No increase in size of other nodes, liver or spleen. Splenic and hepatic nodules must have regressed by ≥50% in the SPD or GTD (for single nodules). With the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present. No progression of non-target disease or new lesions. (NCT01055496)
Timeframe: From first dose of study medication through 2 year follow-up period, including but not limited to planned assessments scheduled every 9 to 24 weeks.

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the DE Cohorts

Intervention	Percentage of participants (Number)
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	81.3
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	53.6

Measure includes death from any cause, PD (including symptomatic deterioration) during and after treatment or initiation of new anticancer therapy for the lymphoma. PD was defined as symptomatic deterioration and according to the International Response Criteria for NHL: 1) appearance of any new lesion >1.5 cm in any axis during or at EOT, even if other lesions are decreasing, 2) at least a 50% increase from nadir in the SPD of any previously involved or single involved nodes, or the size of other lesions (splenic or hepatic). Lymph nodes with a short axis diameter of <1.0 cm must increase by ≥50% and to a size of 1.5x1.5 cm or >1.5 cm in the long axis, 3) 50% increase in the longest diameter of any single previously identified node >1 cm in its short axis. PD was defined as clinical PD, new non-nodal lesions or new nodal lesion ≥1.5 cm in GTD, progression of existing non-index lesions or bone marrow that was negative and now positive. (NCT01055496)
Timeframe: 6, 12 and 24 months

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts.

Intervention	Percent Probability (Number)
	6 months	12 months	24 months
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	80.00	66.67	22.22
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	60.98	47.92	33.54

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the DE Cohorts

Intervention	Percent Probability (Number)
	6 months	12 months	24 months
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	61.85	51.54	44.67
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	54.74	24.88	NA

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: 6, 12, and 24 months

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts

Intervention	Percent Probability (Number)
	6 months	12 months	24 months
DE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	100.00	80.00	80.00
DE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	74.07	62.96	55.09

OS was defined from date of first dose to date of death due to any cause, censoring at the date of last contact. (NCT01055496)
Timeframe: 6, 12, and 24 Months

Mean Inotuzumab Ozogamicin Serum Concentrations

Intervention	Percent Probability (Number)
	6 months	12 months	24 months
MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	84.38	78.13	71.61
MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	88.00	59.11	53.74

Pharmacokinetic (PK) samples were required for participants enrolled in the confirmatory and preliminary efficacy MTD cohorts only (Parts 2 and 3). Concentrations of inotuzumab ozogamicin in serum were determined using appropriate, validated unconjugated (also known as free) bioanalytical assays. (NCT01055496)
Timeframe: Pre-dose on Cycle 1, Day 2; Pre-dose, 1 and 3 hours post-dose on Cycle 3, Day 2; 24 hours post-dose on Cycle 3, Day 3 and 168 hours post-dose on Cycle 3, Day 8.

Mean Inotuzumab Ozogamicin Serum Concentrations

Intervention	ng/mL (Mean)
	Cycle 1 Day 2, 0h
Cohort 1, Arm 2	NA
Cohort 3b, Arm 2	NA
Cohort 4, Arm 1	NA
Cohort 4, Arm 2	NA

Percentage of Participants With a Treatment Emergent AE

Intervention	ng/mL (Mean)
	Cycle 1 Day 2, 0h	Cycle 3 Day 2, 0h	Cycle 3 Day 2, 1h	Cycle 3 Day 2, 3h	Cycle 3 Day 3, 24h	Cycle 3 Day 8, 168h
Cohort 2b/MTD/EE Arm 2: (R-GDP) Plus Inotuzumab Ozogamicin	NA	25.00	283.27	280.33	154.25	NA
Cohort 3/MTD/EE Arm 1: (R-CVP) Plus Inotuzumab Ozogamicin	NA	NA	189.74	213.95	110.39	NA

An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event may not necessarily have had a causal relationship with the treatment or usage. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were defined as those occurring on or after the first study drug dose day through and including 56 days post last dose of study drug. The severity of all AEs was graded by the investigator using the National Cancer Institute Common Terminology Criteria for AE Version 3.0 (NCI CTCAE v3.0). (NCT01055496)
Timeframe: SAEs were assessed from informed consent through and including the end of treatment visit (at least 28 calendar days after last study drug administration). Non-SAEs were recorded from time of the first dose of study drug through last participant visit.

Hemoglobin A1c

Length of Insulin Therapy (Days)

Intervention	Percentage of Participants (Number)
	Subjects with AEs	Subjects with SAEs	Subjects with Grade 3 or 4 AEs	Subjects with Grade 5 AEs	Subjects discontinued due to AEs	Subjects with dose reduced due to AEs	Subjects with temporary discontinuation due to AEs
Arm 1 (R-CVP) Plus Inotuzumab Ozogamicin	100	31.3	89.6	4.2	27.1	16.7	54.2
Arm 2 (R-GDP) Plus Inotuzumab Ozogamicin	100	45.5	96.4	5.5	36.4	32.7	67.3

Intervention	percent of hemoglobin (Mean)
Metformin and Insulin Therapy	4.8

(NCT01486043)
Timeframe: During the 30 days of induction chemotherapy (plus or minus 2 weeks)

Serum Fructosamine Level

Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .

Intervention	days (Mean)
Metformin and Insulin Therapy	7.5

(NCT00389818)
Timeframe: After cycles 2, 4, 6, 1 month after treatment discontinuation, every 2 months for 1 year after treatment discontinuation, every 6 months during the second and third years after treatment discontinuation

Article	Year
Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cyclophosphamide; Doxorubici	2022
Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis. Critical reviews in oncology/hematology, 2021, Volume: 167 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl	2021
Follicular Lymphoma: a Focus on Current and Emerging Therapies Oncology (Williston Park, N.Y.), 2022, 02-08, Volume: 36, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydr	2022
Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose? American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2022, Volume: 42 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Fol	2022
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma. Acta medica Indonesiana, 2022, Volume: 54, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide;	2022
Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia. British journal of haematology, 2022, Volume: 199, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; British Columbia; Cyclophosphamide; Doxorubicin; Hum	2022
Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. International immunopharmacology, 2022, Volume: 113, Issue:Pt A Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl	2022
Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us? Blood reviews, 2023, Volume: 61 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl	2023
Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review. Journal of Zhejiang University. Science. B, 2023, Aug-15, Volume: 24, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus In	2023
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica, 2020, Volume: 105, Issue:7 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nerv	2020
Long-term endoscopic remission in Crohn's disease after allogeneic hematopoietic stem cell transplantation for diffuse large B cell lymphoma: case report and literature review. Clinical journal of gastroenterology, 2021, Volume: 14, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Crohn Disease; Cyclophosphamide; Doxorubicin;	2021
Treatment of mantle cell lymphoma in older adults. Journal of geriatric oncology, 2018, Volume: 9, Issue:4 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop	2018
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Current treatment options in oncology, 2018, 07-21, Volume: 19, Issue:9 Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P	2018
[New case of intradural extramedullary capillary haemangioma]. Revista de neurologia, 2018, 08-16, Volume: 67, Issue:4 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arter	2018
Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma. Current treatment options in oncology, 2018, 09-10, Volume: 19, Issue:11 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv	2018
[MYC-associated B-cell lymphomas: pathophysiology and treatment]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2019, Volume: 60, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp	2019
Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma. Current cancer drug targets, 2019, Volume: 19, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neop	2019
Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leukemia & lymphoma, 2014, Volume: 55, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy	2014
The optimal management of follicular lymphoma: an evolving field. Drugs, 2013, Volume: 73, Issue:13 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine	2013
Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse). Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami	2014
[Treatment strategy of Hodgkin lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; B	2014
The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer. Current treatment options in oncology, 2015, Volume: 16, Issue:2 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Ph	2015
Xanthomatous hypophysitis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015, Volume: 22, Issue:7 Topics: Aged; Anti-Inflammatory Agents; Biopsy; Female; Histiocytes; Humans; Magnetic Resonance Imaging; Neo	2015
Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission. Current treatment options in oncology, 2015, Volume: 16, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation;	2015
[Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:10 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl	2015
Maintenance therapy for multiple myeloma in the era of novel agents. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematolog	2015
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. Vnitrni lekarstvi, 2016, Volume: 62, Issue:1 Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc	2016
Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma. Current stem cell research & therapy, 2017, Volume: 12, Issue:1 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy	2017
A rare case of non-Hodgkin lymphoma in a pacemaker pocket. Leukemia & lymphoma, 2009, Volume: 50, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Device Remo	2009
Primary cutaneous marginal zone B-cell lymphoma with amyloid deposition: report of two cases with review of literature. Chinese journal of cancer, 2010, Volume: 29, Issue:6 Topics: Aged; Amyloidosis; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; D	2010
[Recent advance in peripheral T-cell lymphoma, not otherwise specified]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2010, Volume: 39, Issue:5 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antige	2010
Primary breast lymphoma. Leukemia & lymphoma, 2003, Volume: 44, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis	2003
Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. Journal of the American Academy of Dermatology, 2004, Volume: 51, Issue:1 Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality The	2004
Diffuse large B-cell lymphoma. Seminars in radiation oncology, 2007, Volume: 17, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti	2007
[The practice of chemotherapy with the DeVita protocol]. Deutsche medizinische Wochenschrift (1946), 1982, Jul-09, Volume: 107, Issue:27 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazin	1982
Response of esthesioneuroblastoma to chemotherapy. Report of five cases and review of the literature. Cancer, 1984, Mar-01, Volume: 53, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy;	1984
Hormone-refractory (D3) prostate cancer: refining the concept. Urology, 1995, Volume: 46, Issue:2 Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Hu	1995
[Elderly non-Hodgkin's lymphoma arising in left brachial soft tissue]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1993, Volume: 30, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Bleomycin; Combined Modality Therapy; Cyc	1993
Hematopoietic stem cell transplants for multiple myeloma. Leukemia & lymphoma, 1996, Volume: 22, Issue:1-2 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marro	1996
[Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center]. Sangre, 1998, Volume: 43, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Combined	1998
[Primary MALT-type lymphoma of the breast]. Sangre, 1998, Volume: 43, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph	1998
Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Annals of hematology, 2001, Volume: 80 Suppl 3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Sys	2001
[New combination chemotherapy in refractory rhabdomyosarcoma of the prostate: a case report and review of the literature]. Hinyokika kiyo. Acta urologica Japonica, 1987, Volume: 33, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child, Preschool; Cisplatin; Combined Mod	1987
Chemotherapy of primary brain tumors. Neurologic clinics, 1985, Volume: 3, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl	1985
Adjuvant systemic therapy for resectable breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms	1985

Article	Year
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. European journal of cancer (Oxford, England : 1990), 2021, Volume: 157 Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined C	2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. International journal of radiation oncology, biology, physics, 2022, 03-15, Volume: 112, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Doxorubic	2022
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood advances, 2022, 10-11, Volume: 6, Issue:19 Topics: Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans;	2022
Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis. Blood, 2022, 09-08, Volume: 140, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Doxorubicin; Eto	2022
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. The New England journal of medicine, 2022, 11-03, Volume: 387, Issue:18 Topics: Adolescent; Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protoc	2022
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis. Blood advances, 2023, 08-08, Volume: 7, Issue:15 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv	2023
Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis: A 2-Step Double-Blind Randomized Clinical Trial. JAMA dermatology, 2023, 04-01, Volume: 159, Issue:4 Topics: Adult; Alopecia Areata; Double-Blind Method; Female; Humans; Male; Methotrexate; Neoplasm Recurrence	2023
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. Leukemia, 2023, Volume: 37, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Lar	2023
Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled «TOASST" (Taper Or Abrupt Steroid STop) multicenter trial. PloS one, 2023, Volume: 18, Issue:4 Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Glucocorticoids; Humans; Multicenter Stud	2023
Efficacy of two different dosages of prednisone for treatment of subacute thyroiditis: a single-centre, prospective, randomized, open-label, non-inferiority trial. Endokrynologia Polska, 2023, Volume: 74, Issue:2 Topics: Humans; Neoplasm Recurrence, Local; Prednisone; Prospective Studies; Thyroiditis, Subacute; Treatmen	2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. Hematological oncology, 2023, Volume: 41, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide;	2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma. Blood advances, 2023, 09-12, Volume: 7, Issue:17 Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mutation; Neopla	2023
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial. British journal of haematology, 2023, Volume: 202, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease-Free Survival; Hemat	2023
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. Blood advances, 2020, 08-11, Volume: 4, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Endothelial Cells; Hu	2020
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica, 2020, 09-01, Volume: 105, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly	2020
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. Leukemia & lymphoma, 2018, Volume: 59, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up St	2018
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Oct-01, Volume: 28, Issue:10 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv	2017
Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma. Medicine, 2017, Volume: 96, Issue:45 Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; C	2017
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 03-01, Volume: 29, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin	2018
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4 Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols	2019
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood, 2013, Aug-15, Volume: 122, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cycl	2013
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-20, Volume: 32, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemoradiotherap	2014
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. Journal of immunology research, 2014, Volume: 2014 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2014
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. Journal of immunology research, 2014, Volume: 2014 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2014
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. Journal of immunology research, 2014, Volume: 2014 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2014
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. Journal of immunology research, 2014, Volume: 2014 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2014
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. British journal of haematology, 2015, Volume: 168, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fe	2015
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. British journal of haematology, 2015, Volume: 168, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib;	2015
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. The Lancet. Oncology, 2015, Volume: 16, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D	2015
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:1 Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antin	2016
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate cancer and prostatic diseases, 2016, Volume: 19, Issue:1 Topics: Adult; Aged; Disease-Free Survival; Docetaxel; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle	2016
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. British journal of haematology, 2016, Volume: 173, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin;	2016
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. British journal of haematology, 2016, Volume: 173, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti	2016
[Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; La	2016
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-01, Volume: 22, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother	2016
Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PloS one, 2016, Volume: 11, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Prepa	2016
[Role of modified radiotherapy in the combined treatment of orbital non-Hodgkin lymphoma]. Voprosy onkologii, 2009, Volume: 55, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cataract; Conjunctivitis; Cyclophospham	2009
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:6 Topics: Administration, Oral; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother	2009
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia, 2010, Volume: 24, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug R	2010
Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. International journal of radiation oncology, biology, physics, 2011, Jul-15, Volume: 80, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin	2011
A long-term follow-up study of prospective 80%-dose CHOP followed by involved-field radiotherapy in elderly lymphoma patients. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F	2011
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia, 2011, Volume: 25, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem	2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doce	2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem	2013
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:5 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agent	2013
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:5 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agent	2013
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:5 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agent	2013
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:5 Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agent	2013
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Deat	2003
Combined modality therapy for poorly differentiated gliomas of the posterior fossa in children: a Children's Cancer Group report. Journal of neuro-oncology, 2003, Volume: 63, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Cell Differentiation; Cereb	2003
High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Nov-01, Volume: 21, Issue:21 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; B-Lymphocytes; Bone Marrow Purging	2003
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:3 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C	2004
Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined	2005
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther	2005
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia, 2006, Volume: 20, Issue:10 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther	2006
ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience. The Korean journal of internal medicine, 2006, Volume: 21, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp	2006
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide	2007
[Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asian People; Asparaginase; Child; Child	2007
Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leukemia & lymphoma, 2007, Volume: 48, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combi	2007
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer, 2008, May-15, Volume: 112, Issue:10 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Respons	2008
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. American journal of clinical oncology, 1984, Volume: 7, Issue:3 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials	1984
A new combination chemotherapy for recurrent Hodgkin's lymphoma. Bangladesh Medical Research Council bulletin, 1982, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Therapy, Co	1982
Follow-up adjuvant chemotherapy and chemoimmunotherapy for stage II and III carcinoma of the breast. Cancer, 1982, May-01, Volume: 49, Issue:9 Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr	1982
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis. American journal of clinical oncology, 1982, Volume: 5, Issue:4 Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphami	1982
A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. American journal of clinical oncology, 1982, Volume: 5, Issue:4 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clin	1982
Hodgkin's disease in the very young. International journal of radiation oncology, biology, physics, 1994, Jan-01, Volume: 28, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschoo	1994
Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. Leukemia & lymphoma, 1994, Volume: 14, Issue:1-2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther	1994
The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients. Cancer, 1994, Dec-01, Volume: 74, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death;	1994
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy	1995
Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet (London, England), 1994, Feb-12, Volume: 343, Issue:8894 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju	1994
Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552. Medical and pediatric oncology, 1994, Volume: 23, Issue:6 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo	1994
Stage III abdominal non-Hodgkin's lymphoma in Costa Rican children: comparison of two consecutive trials of treatment. Medical and pediatric oncology, 1994, Volume: 22, Issue:3 Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasm	1994
Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1993, Volume: 127 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp	1993
Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leukemia & lymphoma, 1996, Volume: 22, Issue:1-2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther	1996
Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast cancer research and treatment, 1996, Volume: 37, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Combined Modality Therapy	1996
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood, 1996, Oct-01, Volume: 88, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Transplantatio	1996
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosph	1998
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anti-cancer drugs, 1999, Volume: 10, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps	1999
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood, 2000, Sep-01, Volume: 96, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells;	2000
A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma. Clinical lymphoma, 2001, Volume: 1, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do	2001
Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Annals of hematology, 2001, Volume: 80 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease	2001
Treatment of refractory Hodgkin's disease with modified Stanford V program. Medical oncology (Northwood, London, England), 2001, Volume: 18, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Epirubicin; Etop	2001
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer, 2002, Mar-15, Volume: 94, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diseas	2002
ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13 Suppl 1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Daca	2002
Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. Lancet (London, England), 1978, Apr-29, Volume: 1, Issue:8070 Topics: Adult; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; D	1978
Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Canadian Medical Association journal, 1979, May-19, Volume: 120, Issue:10 Topics: Adult; Age Factors; Aged; Breast Neoplasms; Clinical Trials as Topic; Female; Follow-Up Studies; Hum	1979
Nitrosoureas in multiple myeloma. Cancer treatment reports, 1976, Volume: 60, Issue:6 Topics: Carmustine; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Human	1976
[Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group]. Medizinische Klinik (Munich, Germany : 1983), 1992, Nov-15, Volume: 87, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant	1992
[Second cessation of therapy in children with acute lymphoblastic leukemia]. Acta haematologica Polonica, 1992, Volume: 23, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophospham	1992
Chemotherapy versus observation in high-risk node-negative breast cancer patients. Journal of the National Cancer Institute. Monographs, 1992, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com	1992
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. British journal of cancer, 1992, Volume: 65, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp	1992
[Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)]. Polskie Archiwum Medycyny Wewnetrznej, 1991, Volume: 86, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; H	1991
Systemic adjuvant therapy in women with resected node-negative breast cancer. Mayo Clinic proceedings, 1991, Volume: 66, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour	1991
Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study. Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans;	1991
Treatment of relapsed acute lymphocytic leukemia in adults. Haematology and blood transfusion, 1990, Volume: 33 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transpl	1990
A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru	1990
The prognostic value of testicular biopsy in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Combined Modality Thera	1990
The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of neurosurgery, 1990, Volume: 72, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Child, Pres	1990
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer, 1990, Jan-15, Volume: 65, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour	1990
Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:3 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cause of Death; Combined Modality Therapy; Female; Follow	1990
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. Journal of neuro-oncology, 1989, Volume: 7, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi	1989
Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials	1989
Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Child; Clinical Tr	1989
Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. Breast cancer research and treatment, 1989, Volume: 13, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined	1989
Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. Cancer, 1989, Nov-01, Volume: 64, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; C	1989
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. The New England journal of medicine, 1989, Feb-23, Volume: 320, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy;	1989
Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined	1988
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M). Japanese journal of clinical oncology, 1988, Volume: 18, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans	1988
Age as a prognostic factor in recurrent breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:5 Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined	1986
Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. Journal of neurosurgery, 1987, Volume: 66, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil	1987
Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined	1985
Adjuvant systemic therapy for resectable breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms	1985
[Cooperative studies in the treatment of acute lymphoblastic leukemia in children in Austria--report of 10 years' experience]. Wiener klinische Wochenschrift, 1985, Feb-01, Volume: 97, Issue:3 Topics: Asparaginase; Austria; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Cytarabi	1985
Total care of the patient with a brain tumor with consideration of some ethical issues. Neurologic clinics, 1985, Volume: 3, Issue:4 Topics: Brain Neoplasms; Clinical Trials as Topic; Dexamethasone; Ethics; Humans; Neoplasm Recurrence, Local	1985
Treatment of histiocytic lymphoma in Uganda adults. East African medical journal, 1971, Volume: 48, Issue:10 Topics: Adult; Cyclophosphamide; Drug Combinations; Evaluation Studies as Topic; Female; Humans; Hydrazines;	1971

prednisone and Local Neoplasm Recurrence

Research Excerpts

Research

Studies (497)

Authors

Clinical Trials (28)

Trial Overview

Trial Outcomes

Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)

Objective Response Rate (ORR) Per IRF at End of Treatment

Overall Survival (OS)

Progression-free Survival Per Independent Review Facility (IRF)

Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)

Incidence of Adverse Events (AEs)

Incidence of Laboratory Abnormalities

Event Free Survival (EFS)

Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).

Intensive Therapy Free Survival (ITFS).

Overall Survival

Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death

Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale

Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review

Disease-free Survival (DFS)

Lymphoma-specific Survival (LSS)

Overall Survival (OS)

Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)

Continuous Complete Remission Since Week 56 Therapy.

Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).

Overall Event-free Survival (EFS)

Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells

Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells

Minimal Residual Disease (MRD)

Number of Participants With Complete Response Rate (CR) at 8 Weeks Post Single Agent Induction

Number of Participants With Complete Response Rate (CR) at up to 12 Months Post MONO - Monotherapy: Ublituximab or Combotherapy: Ublituximab + Umbralisib.

Overall Response Rates (ORR) for Number of Participants

Kaplan-Meier Estimate of the OS in the MTD Confirmation/EE Cohorts

Kaplan-Meier Estimate of the Overall Survival (OS) in the DE Cohorts

Kaplan-Meier Estimate of the PFS in the MTD Confirmation/EE Cohorts

Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in the DE Cohorts

Participants Reporting DLT AEs for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 2

Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1

Percentage of Participants With a Best OR of CR or PR According to International Response Criteria for NHLs in the DE Cohorts

Percentage of Participants With Any Grade 3/4 Chemistry Abnormality During Therapy

Percentage of Participants With Any Grade 3/4 Hematology Abnormality During Therapy

Percentage of Participants With Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) According to International Response Criteria for NHLs in the MTD and EE Cohorts

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the DE Cohorts

Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts.

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the DE Cohorts

Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts

Mean Inotuzumab Ozogamicin Serum Concentrations

Mean Inotuzumab Ozogamicin Serum Concentrations

Percentage of Participants With a Treatment Emergent AE

Hemoglobin A1c

Length of Insulin Therapy (Days)

Serum Fructosamine Level

Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .

Reviews

Trials

Other Studies